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CHAPTER I 
 
INTRODUCTION 
 
Molecular mechanisms of translation initiation  
 
Protein synthesis is an essential cellular process where genomic 
information encoded on messenger RNA (mRNA) molecules is decoded by the 
translation machinery and transformed into polypeptides, or proteins.  Ribosomes 
translate mRNA and synthesize proteins using amino acids delivered by transfer 
RNA (tRNA). The translation machinery consists of the ribosome and other 
associated regulatory proteins, known collectively as translation factors.  The 
eukaryotic ribosome is comprised of two subunits that are named due to their 
different sedimentation coefficients.  The 40S ribosomal subunit is a stable 
complex of 33 separate polypeptides and an 18S ribosomal RNA (Dinman 2008).  
The 60S subunit contains 46 proteins and 3 different rRNA molecules, 28S, 5.8S, 
and 5S (Dinman 2008).  Aminoacyl tRNAs are short RNA molecules that transfer 
a specific amino acid to a growing polypeptide chain during translation.  tRNAs 
contain a three base region called the anticodon that can base pair to the 
corresponding three base codon region on mRNA (Jackson, Hellen et al. 2010).   
Each tRNA can be uniquely attached to only one of the 20 amino acids.  The 
translationally active form of the ribosome is the 80S ribosome, made up of the 
40S and 60S subunits in complex with other essential translation factors, an 
mRNA molecule, the translation factors, and aminoacyl tRNAs.   
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Before a particular messenger RNA can be translated, a number of 
concerted molecular events need to occur.  The process of protein synthesis is 
broken down into three distinct steps initiation, elongation, and termination.  
Initiation, the first step in protein synthesis, comprises all of the necessary events 
up to the formation of a translationally active 80S ribosome localized at the start 
codon base-paired with the initiation methionyl tRNA.  Elongation is the active 
process of the ribosome decoding the information contained in the codons of the 
mRNA producing polypeptides through the ribosome’s peptidyl transferase 
activity.  Using the mRNA as a template, the ribosome traverses each codon  of 
the mRNA, pairing it with the appropriate amino acid provided by a tRNA. 
Peptide bond formation is actually catalzyed by the 23S rRNA within the 60S 
subunit (Jackson, Hellen et al. 2010).  Termination is the last step in the process 
and involves recognition of the stop codon and subsequent mRNA release and 
disassembly of the active 80S ribosome into its 40S and 60S subunits.  While 
each step in protein synthesis has multiple, distinct levels of regulation, 
translation initiation is the most highly regulated and complex step in the process 
(Jackson, Hellen et al. 2010).    
The mechanism of eukaryotic translation initiation is an area of intense 
study due to the complexity of selecting temporally and spatially which mRNA 
molecules should be translated.  Ignoring the large number of signaling pathways 
that converge upon the translation initiation machinery to regulate its activity, the 
general mechanism of initiation is still extremely complex and an area of active 
research (Van Der Kelen, Beyaert et al. 2009; Jackson, Hellen et al. 2010).   
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The consensus mechanism for translation initiation in eukaryotes is known 
as the scanning model (Kozak 1989; Kozak 1999).  Briefly, in this model, the 40S 
ribosome binds to the 5’ cap structure of an mRNA molecule and translocates, or 
“scans” along the mRNA looking for an AUG start codon.  When the scanning 
40S ribosome locates the start codon and the methionyl  initator tRNA base-pairs 
with the start codon, the 60S ribosomal subunit is recruited, thereby forming the 
translationally active 80S subunit (Jackson, Hellen et al. 2010).   
The scanning model for translation initiation relies on the ability of the 
ribosome or associated translation factors to bind to the 5’ region of an mRNA 
molecule and begin the scanning process.  Prokaryotic messenger RNA contains 
specific sequences, known as the Shine-Dalgarno sequence, which directly 
recruits the small ribosomal subunit and initiation factors to internal sites on the 
mRNA within 5-10 nucleotides from the start codon (Shine and Dalgarno 1975).  
In eukaryotes, a consensus sequence that recruits the translation machinery is 
mediated by a 7-methyl-guanosine cap structure at the 5’ end of the mRNA 
(Furuichi, Morgan et al. 1975; Furuichi, Muthukrishnan et al. 1975; Furuichi, 
Muthukrishnan et al. 1976).  The eukaryotic initiation factor eIF4E, a member of 
the eIF4F complex, specifically recognizes and binds to the 7-methylguanosine 
cap (Sonenberg, Rupprecht et al. 1979).  The other members of eIF4F serve 
essential roles in translation initiation and the recruitment of the 40S small 
ribosomal subunit.  eIF4G acts as a scaffolding protein, mediating the recruitment 
of the 40S subunit -bound eIF3 to the cap-bound eIF4E.    The eIF4F complex 
and the 40S subunit scan along the 5’ untranslated region of the mRNA until the 
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complex reaches the initiation codon, AUG (Kozak 1980; Kozak 1980).  Cellular 
mRNAs lacking the 7-methylguanosine cap structure are either inefficiently 
translated or not translated at all, suggesting that the cap structure is required for 
the initiation of translation (Kapp and Lorsch 2004).   
 
Not all translation initiation in eukaryotes requires the 5’ cap structure 
 Even though the scanning model explains the mechanistic details 
associated with initiating translation of 7-methyl-guanosine-capped mRNAs, it 
fails to explain translation of certain uncapped RNA sequences and translation of 
specific mRNA when cap-dependent initiation is inhibited.  Certain mRNAs, such 
as those derived from the picornavirus family, are not capped, yet they are 
translated efficiently in eukaryotic cells (Pelletier and Sonenberg 1988; Jang, 
Davies et al. 1989).  The discovery that the 5’UTR of poliovirus could initiate 
translation in the absence of the 5’ cap complex suggested an alternative 
mechanism for eukaryotic translation initiation (Pelletier and Sonenberg 1988).  
5’UTR elements that could support translation initiation even in the uncapped 
form were called internal ribosome entry sites (IRES) (Pelletier, Kaplan et al. 
1988; Pelletier and Sonenberg 1988).  A number of different viruses were found 
to contain IRES structures, that could initiate translation at internal  sites of the 
mRNAs independent of the 5’ end (Wilson, Powell et al. 2000; Liljas, Tate et al. 
2002), suggesting that internal ribosome entry might represent a mechanism 
used by viruses to bypass eukaryotic control mechanisms.  Indeed, many 
picornaviruses encode a protease that specifically cleaves the eukaryotic  
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cap-binding protein, eIF4G, rendering host cap-dependent translation inactive 
and stimulating translation of viral IRES-containing transcripts (Haghighat, Svitkin 
et al. 1996; Bushell and Sarnow 2002).  
IRES-mediated translation, despite occurring in the absence of a 5’ cap 
structure, still requires the recruitment of the ribosome and translation machinery 
to the mRNA.  Initially, the Sonenberg group suggested that the IRES RNA 
sequences or structures themselves could recruit the small ribosomal subunit, 
much like the Shine-Dalgarno sequence functions in prokaryotic organisms.  
Early work with the cricket paralysis virus (CrPV) IRESs provided a completely 
novel mechanism for translation initiation and ribosome recruitment.  The Sarnow 
group discovered that the CrPV IRES adopts a structure similar to the initiator 
tRNA molecule and directly recruits the ribosome in the absence of other protein 
cofactors.  The IRES RNA localizes directly in the P-site of the ribosome and 
mimics tRNA binding, thus facilitating translation elongation (Wilson, Pestova et 
al. 2000; Wilson, Powell et al. 2000; Spahn, Jan et al. 2004).  This method of 
recruitment and initiation seems to be unique to just the CrPV IRES, suggesting 
that other recruitment mechanisms existed for other IRESs (Pestova and Hellen 
2003).   
Discovery of the La protein suggested an alternative mechanism for 
ribosomal recruitment to IRESs (Meerovitch, Pelletier et al. 1989).  The La 
protein is capable of binding to the IRES-containing region of the poliovirus 
mRNA,  promoting IRES-mediated translation (Meerovitch, Pelletier et al. 1989; 
Meerovitch, Svitkin et al. 1993).  Proteins that can bind to IRESs and facilitate 
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cap-independent translation are named IRES-trans-acting factors, or ITAFs 
(Stoneley and Willis 2004).  It is unlikely that eukaryotic cells have evolved to 
produce proteins whose function involves helping viruses replicate and prosper.  
ITAFs, therefore, are proposed to perform functions that are important to 
eukaryotic cells unrelated to the translation of viral mRNAs that will be discussed 
later. 
 
Eukaryotic cellular mRNAs also contain internal ribosome entry sites 
 In 1991, Sarnow and colleagues discovered that the human 
immunoglobulin binding protein (BiP) mRNA could be translated in a cap-
independent fashion (Macejak and Sarnow 1991), providing the first evidence 
that IRESs were present in non-viral mRNAs.  Soon after, many other human 
mRNAs were discovered to contain IRESs (Oh, Scott et al. 1992; Vagner, 
Gensac et al. 1995; Gan and Rhoads 1996).  Interestingly, previously discovered 
ITAFs of viral IRESs also regulated the function of cellular IRESs, suggesting 
that viral and cellular IRESs may activate translation through similar 
mechanisms.  Cellular and viral IRESs do not share any significant sequence 
homology, leading researchers to posit that structural or cofactor similarity 
mediates IRES function (Hellen 2010).    ITAFs are believed to bind to IRES RNA 
and act as RNA chaperones, folding the RNA into a structure that is directly 
recognized by the ribosome (Stoneley and Willis 2004; Mitchell, Spriggs et al. 
2005).  This also suggests that cellular ITAFs may not recognize structures, but 
rather recognize specific RNA sequences within the IRES.  Structural 
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characterization of cellular IRESs with associated ITAFs and translation 
machinery would be extremely beneficial in dissecting the mechanism of action 
for cellular IRESs.   
Immediately after the discovery of eukaryotic cap-independent translation, 
researchers questioned why mRNAs contained IRESs, since even IRES-
containing cellular mRNAs are capped at the 5’ end.  Sarnow and colleagues 
initially hypothesized that cellular mRNAs might contain IRESs in order to 
support translation of certain mRNAs during mitosis, a time when cap-dependent 
translation is severely reduced (Bonneau and Sonenberg 1987; Huang and 
Schneider 1991; Macejak and Sarnow 1991).  This hypothesis was confirmed by 
the discovery that the IRES of the ornithine decarboxylase (ODC) mRNA was 
active predominantly during mitosis, and that ODC protein activity is required for 
progression from mitosis (Fredlund, Johansson et al. 1994; Fredlund, Johansson 
et al. 1995; Fredlund and Oredsson 1996; Pyronnet, Pradayrol et al. 2000).  
Additional physiological events, such as environmental stress, apoptosis, UV 
irradiation, and viral infection see increased levels of cap-independent translation 
((Stoneley, Chappell et al. 2000; Stoneley and Willis 2004; Spriggs, Stoneley et 
al. 2008 ).  Overall, IRES-containing mRNAs are thought to be translated in 
response to a situation where increased levels of the protein are needed, but 
cannot be synthesized through normal cap-dependent mechanisms.   
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Internal ribosome entry site-mediated translation of the ornithine 
decarboxylase mRNA 
 
 Ornithine decarboxylase (ODC) is an essential cellular enzyme that 
catalyzes the conversion of ornithine to putrescine, which is eventually converted 
into other polyamines by downstream enzymes (Kay, Singer et al. 1980).  
Polyamines are required for cell cycle progression and DNA synthesis, and 
depletion of cellular polyamines results in cell cycle arrest (Kay, Singer et al. 
1980; Laitinen, Stenius et al. 1998; Shantz and Levin 2007).  The mechanism of 
polyamine action is poorly understood, but is thought to involve a combination of 
DNA, RNA, and protein interactions (Berlaimont, Pauwels et al. 1997; Laitinen, 
Stenius et al. 1998).  Supplementing growth media with polyamines confers a 
selective growth advantage to tissue culture cells. Mutations that increase ODC 
activity are associated with a number of human cancers (Leinonen, Alhonen-
Hongisto et al. 1987; Polvinen, Sinervirta et al. 1988; Elitsur, Koh et al. 1995; 
Tamori, Nishiguchi et al. 1995; Brabender, Lord et al. 2001; Sanchez Mas, 
Martijnez-Esparza et al. 2002).  A number of chemotherapeutic agents target the 
polyamine biosynthesis pathway, in particular the ODC enzyme, because 
inhibition of polyamine biosynthesis results in cell cycle arrest and apoptosis 
(Pegg, Shantz et al. 1995; Shantz and Levin 2007).   
The requirement for polyamine biosynthesis during mitosis suggested that 
the activity or expression of these enzymes is upregulated during the cell cycle.  
Indeed, ODC and other polyamine biosynthetic enzymes have increased 
expression during G1/S phase, a period of cellular growth, and during the G2/M 
transition, a period of cellular stress during mitosis 
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(Dircks, Grens et al. 1986; Park, Wolff et al. 1993; Fredlund, Johansson et al. 
1995)}.  As previously discussed, the ODC mRNA was determined to contain an 
IRES that is active during the G2/M transition, resulting in increased levels of the 
ODC protein (Pyronnet, Pradayrol et al. 2000).  Attaching the ODC 5’UTR to the 
ORF of an unrelated gene confers translation during mitosis.  Addition of a stable 
hairpin structure directly upstream of the IRES blocks cap-dependent translation, 
due to an inability of the ribosome to scan, but does not affect internal ribosome 
entry and translation initiation.  Finally, Sonenberg and colleagues mutated 
polypyrimidine tracts in the ODC IRES and found that they were required for 
internal ribosome entry (Pyronnet, Pradayrol et al. 2000).  This groundbreaking 
work provided a bona fide physiological role for internal ribosome entry site 
mediated translation of cellular mRNAs.  Despite the importance of these results, 
the mechanisms and proteins regulating cap-independent translation of the ODC 
IRES were still unclear.   
Mutating the polypyrimidine tract of the ODC IRES to purines abolished 
cap-independent translation of ODC during the G2/M transition (Pyronnet, 
Pradayrol et al. 2000).  This result suggests that these mutations either altered 
the RNA secondary structure or altered the sequence required for recognition by 
ITAFs to recruit the ribosome.  Work by Vincent Gerbasi in Dr. Andrew Link’s 
laboratory provided insight into the mechanism of ODC IRES-mediated 
translation.  Using RNA affinity chromatography of the wild-type and mutated 
ODC IRES sequences followed by highly sensitive LC-MS/MS analysis, Gerbasi 
was able to isolate two proteins that bound to the wild-type, but not mutant forms 
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of the IRES.  These proteins were identified as poly(C) binding protein 2 
(PCBP2) and zinc finger 9 (ZNF9).  Functional analysis of PCBP2 and ZNF9 in 
ODC IRES-dependent translation suggested that the two proteins acted as 
ITAFs.  While PCBP2 is a known ITAF for viral internal ribosome entry sites, the 
conclusion that ZNF9 regulates cap-independent translation was a novel finding.  
Interestingly, little is known about the functional activity of the ZNF9 protein.   
 
The discovery and in vitro biochemical characterization of the ZNF9 gene 
 
The zinc finger 9 gene (ZNF9), also known as cellular nucleic acid binding 
protein, (CNBP), was initially identified as a protein capable of binding the sterol 
regulatory element (SRE) of the HMG-coA-reductase promoter by a yeast 1 
hybrid screen (Rajavashisth, Taylor et al. 1989).  Even though the protein had 
single stranded DNA binding activity, the protein was purposely named cellular 
nucleic acid binding protein because of its amino acid sequence.  Primary 
sequence analysis of ZNF9 revealed the presence of seven CCHC zinc finger 
sequences (Rajavashisth, Taylor et al. 1989) and an RGG box domain.  The  
CCHC zinc fingers have the consensus sequence (C-Ar-X-C-G-X-X-X-H-X-X-XX-
C), where Ar represents an aromatic amino acid and X is a variable amino acid.  
While other zinc finger motifs are commonly found in DNA binding proteins, the 
CCHC-type zinc finger is most commonly associated with the nucleocapsid 
domain of the human immunodeficiency virus 1 (HIV1) (Bombarda, Grell et al. 
2007; Grigorov, Decimo et al. 2007).  The nucleocapsid protein binds to the  
HIV-1 RNA genome and regulates its stability and replication 
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(De Guzman, Wu et al. 1998).  RGG boxes bind single stranded RNA and are 
found in a number of translation factors and RNA chaperones (Darnell, Warren et 
al. 2004; Darnell, Mostovetsky et al. 2005).   The presence of these different 
motifs normally used to bind RNA suggested that ZNF9 may have additional 
functions beyond the regulation of the sterol regulator element.  Indeed, follow-up 
studies demonstrated that rat ZNF9, identical to the human protein, could bind 
both single stranded RNA and DNA (Yasuda, Mashiyama et al. 1995).   
The use of yeast 1 hybrid screening libraries and DNA affinity 
chromatography to isolate sequence specific DNA binding proteins revealed 
ZNF9 as a putatively promiscuous regulator of transcription.  ZNF9 was reported 
to control transcription of the c-myc gene through interactions with the CT 
element in the c-myc promoter (Michelotti, Tomonaga et al. 1995).  Additionally, 
ZNF9 was found to bind to an enhancer of the JC polyoma virus, the promoters 
of the B-myosin heavy chain and the M-CSF1 genes, further suggesting that 
ZNF9 functions as a transcriptional regulator (Flink and Morkin 1995; Konicek, 
Xia et al. 1998; Liu, Kumar et al. 1998).  All of the promoters used as bait to 
isolate ZNF9 contain guanine-rich stretches that were postulated to be the 
preferred target of ZNF9.   
The ability of ZNF9 to bind to G-rich stretches was supported by the 
discovery that ZNF9 regulates the translation of Xenopus laevis ribosomal 
proteins with G-rich 5’ untranslated regions (Pellizzoni, Lotti et al. 1997).  Using 
RNA affinity chromatography, Paola Pierandrei-Amaldi and colleagues 
discovered that ZNF9 along with the La protein binds to the 5’UTR of ribosomal 
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proteins promoting translation of these mRNAs (Cardinali, Di Cristina et al. 1993; 
Pellizzoni, Lotti et al. 1997; Pellizzoni, Lotti et al. 1998).  Another study showed 
CNBP also binds to G-rich regions within nascent c-myc transcripts (Yasuda, 
Mashiyama et al. 1995).   
Work performed mainly in the lab of Nora Calcaterra sheds light onto the 
in vitro RNA and DNA binding activity of ZNF9.  Using primarily electrophoretic 
mobility shift assays, the Calcaterra group has systematically analyzed ZNF9 
binding to DNA and RNA oligonucleotides of varying sequence and length 
(Lombardo, Armas et al. 2007; Armas, Nasif et al. 2008; Borgognone, Armas et 
al. 2010).  Ultimately, ZNF9 binds to single stranded RNA or DNA, but not double 
stranded DNA.  ZNF9 binds with approximately equal affinity to RNA or DNA, 
with a very strong preference for G-rich nucleic acids, similar to the probe 
sequences used to pulldown and identify ZNF9 in previous studies (Armas, Nasif 
et al. 2008).  While there does not seem to be a difference in affinity for RNA or 
DNA, ZNF9 may form dimers during interactions with RNA, but not with DNA 
(Armas, Nasif et al. 2008).  EMSA analysis reveals that ZNF9 may act as a 
nucleic acid chaperone, stimulating DNA and RNA annealing, and that this 
activity may explain ZNF9s ability to stimulate transcription and translation 
(Lombardo, Armas et al. 2007; Armas, Nasif et al. 2008; Borgognone, Armas et 
al. 2010).  Characterization of the in vitro biochemistry of ZNF9 provides insight 
into the mechanism of action and into possible in vivo nucleic acid targets, but 
does not give any information into the functional and physiological role for the 
ZNF9 protein.   
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Studying the in vivo role of the ZNF9 protein 
 Soon after the initial cloning and discovery of ZNF9, a homolog was 
discovered in Schizosaccharomyces pombe, providing the first experimental data 
of a ZNF9 phenotype.   A null allele of byr3, the putative homolog, caused drastic 
reductions in the sporulation efficiency of diploid yeast, a phenotype that was 
rescued by expression of the human znf9 gene (Xu, Rajavashisth et al. 1992).  
Sporulation in S. pombe is controlled by the yeast ras homolog, suggesting that 
ZNF9 might be part of this important cellular pathway regulating cell growth and 
proliferation.  Characterization of embryonic X. laevis development revealed that 
ZNF9 mRNA is consistently expressed through all developmental phases and 
tissues, providing evidence as to the protein’s physiological importance (Flink, 
Blitz et al. 1998; De Dominicis, Lotti et al. 2000).  ZNF9 mRNA expression data 
from chicken and frog embryos further supported the proposed importance of 
ZNF9 during embryogenesis and later development (Ruble and Foster 1998; 
Calcaterra, Palatnik et al. 1999).   
 The embryonic ZNF9 mRNA expression patterns suggest that the protein 
has functional importance in the development of the embryo.  Using a viral 
integration strategy, the Li lab created a znf9 knockout mouse and provided 
unequivocal evidence of ZNF9s importance in embryonic development (Chen, 
Liang et al. 2003).    Absence of the znf9 gene in homozygous animals results in 
severe truncation of the developing forebrain, correlating well to the ZNF9 mRNA 
expression pattern in the forebrain of mouse embryos (Chen, Liang et al. 2003; 
Shimizu, Chen et al. 2003).  Knockout of znf9 is embryonic lethal by day 13.5.  
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Approximately 40% of mice with one copy of the znf9 gene show severe defects 
in craniofacial development, such as smaller snouts and jaws, and small or 
absent eyes (Chen, Liang et al. 2003).  The requirement for znf9 in craniofacial 
development was confirmed by siRNA knockdown of ZNF9 mRNA in chicken 
embryos and morpholino knockdown in zebrafish embryos (Abe, Chen et al. 
2006; Weiner, Allende et al. 2007).   
 The previous reports of ZNF9s function as a regulator of c-myc expression 
suggested that perhaps the craniofacial defects are caused by losses in c-myc in 
the developing embryo.  C-myc is a well known regulator of cell growth, 
proliferation, and differentiation.  Analysis of c-myc expression in the embryonic 
forebrain revealed completely absent or low c-myc mRNA expression in mutant 
znf9 mice, suggesting that ZNF9 is required for forebrain specification through 
induction of c-myc (Chen, Liang et al. 2003).  Craniofacial tissues in the 
developing embryo are derived from the neural crest tissues (Szabo-Rogers, 
Smithers et al. 2010).  Zebrafish ZNF9 morphants show reduced expression of 
col2A1, crestin, and foxD3, important markers for the developing neural crest 
tissue, indicating that ZNF9 regulates the expression of these genes and 
ultimately might control neural crest development (Weiner, Allende et al. 2007).  
Regions with low or absent ZNF9 expression in ZNF9 morphants showed 
abnormally low cell proliferation and increased apoptosis (Weiner, Allende et al. 
2007), consistent with the previous observation that overexpression of ZNF9 in 
mouse P19 cells increases rates of cell proliferation (Shimizu, Chen et al. 2003).  
Overall, this data suggests that ZNF9 controls craniofacial development through 
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control of cellular proliferation, potentially through induction of c-myc and other 
target genes. 
 Deciphering the function of the ZNF9 protein became more urgent with the 
discovery that mutations in the ZNF9 gene were linked to myotonic dystrophy 
type 2 (DM2).  64 sets of parents and offspring that had clinical features of 
myotonic dystrophy but did not have the mutation responsible for myotonic 
dystrophy type 1 were screened for genomic rearrangements or expansions 
using transmission disequilibrium testing (Liquori, Ricker et al. 2001).  
Subsequent Southern blot analysis and DNA sequencing revealed a variable 
nucleotide expansion within the first intron of znf9 in patients affected with the 
clinical features of myotonic dystrophy (Liquori, Ricker et al. 2001).  While the 
first intron normally contains CCTG microsatellites of varying length, pathological 
expansions in this region were seen up to 48kB in length.  The expansion of 
CCTG in znf9 that causes DM2 is remarkably similar to the CTG expansion in the 
3’UTR of dmpk that results in myotonic dystrophy type 1 (Brook, Mccurrach et al. 
1992).  Because the two diseases have extremely similar clinical manifestations 
and similar nucleotide expansions in seemingly unrelated genes, Ranum and 
colleagues hypothesized that the mechanism for the disease was likely 
independent of the function of either gene (Liquori, Ricker et al. 2001).   
 
General mechanisms of nucleotide expansion repeat disorders 
The myotonic dystrophies (Types 1 and 2) are classified as nucleotide (or 
microsatellite) repeat expansion disorders.  These diseases are also commonly 
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referred to as diseases of unstable repeat expansions (Gatchel and Zoghbi 
2005).  The diseases ultimately result from errors in DNA replication within 
normal tandem repeat regions in the genome, leading to large expansions of the 
repeat region (Nakayabu, Miwa et al. 1998; Xu, Peng et al. 2000; Lahue and 
Slater 2003).  Most of these disorders show increased pathogenicity, either 
earlier onset or increased severity, in subsequent generations, due to the 
increased likelihood of further expansions in mutated gene regions (Carpenter 
1994; La Spada, Paulson et al. 1994; O'Donnell and Zoghbi 1995).  Interestingly, 
although the mutated gene for each disease is different, all known nucleotide 
repeat expansion disorders target the nervous system, suggesting the inherent 
sensitivity of this system to perturbations of normal physiological processes 
(Gatchel and Zoghbi 2005). 
  Within the nucleotide repeat expansion disorder classification, there are 
three general pathogenic mechanisms.  The first are diseases caused by 
nucleotide expansions within or near a gene that results in a loss of function for 
that gene.  The most commonly studied disease of this type is Fragile X 
Syndrome, which is caused by a repeat expansion in 5’UTR of the fmr1 gene 
(Calkhoven, Muller et al. 2002; Gatchel and Zoghbi 2005).   In the case of Fragile 
X Syndrome, expansion of the 5’UTR results in transcriptional and translational 
silencing of the FMR1 gene (Chen, Tassone et al. 2003; Beilina, Tassone et al. 
2004).  The loss of function mechanism is supported by evidence that animals 
lacking the fmr1 share many of the developmental and behavioral abnormalities 
associated with the repeat expansion (Huber, Gallagher et al. 2002; Bear, Huber 
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et al. 2004).  Additionally, a single point mutation in fmr1 that disrupts FMR1 
translational repression gives rise to a severe form of Fragile X, suggesting that a 
direct loss of FMR1 activity leads to development of the disease (Feng, Absher et 
al. 1997).  
The second general mechanism for NRE disorders is caused by a gain of 
function for a mutated gene.  In Huntington’s disease, trinucleotide repeats within 
the coding region of the Huntingtin gene give rise to a mutant protein containing 
a long stretch of glutamine residues (Gatchel and Zoghbi 2005).  These long 
stretches of glutamine residues are common within nucleotide repeat expansion 
disorders and are commonly referred to as polyQ diseases.  The mutant 
Huntingtin protein is inherently disordered, and misfolding of the mutant protein 
leads to formation of intracellular aggregates that lead to cellular toxicity (La 
Spada, Paulson et al. 1994; Gatchel and Zoghbi 2005).  Genetic models 
expressing mutant forms of Huntingtin or other proteins engineered to have large 
glutamine expansions show similar phenotypes, giving support to the gain of 
function model (Watase, Weeber et al. 2002; Yoo, Pennesi et al. 2003).  
Polyglutamine expansion within the Huntingtin gene does severely decrease 
huntingtin protein function, but it is not clear whether this reduction in activity 
contributes to the disease (Dragatsis, Levine et al. 2000; Zuccato, Ciammola et 
al. 2001; Dragatsis, Zeitlin et al. 2004). 
The third and final general mechanism for nucleotide repeat expansion 
disorders is caused by a gain of function of expanded repeat RNA.  The myotonic 
dystrophies are the prototypical members of this family of diseases.  In this 
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proposed mechanism, an affected gene is transcribed and translated normally, 
but the expanded RNA repeat forms secondary structures that render it stable in 
either the cytoplasm or the nucleus.  RNA binding proteins interact with the 
stable RNA and are prevented from performing their normal cellular function.  
Thus far, the stable RNA is thought to interfere with normal RNA splicing, as two 
of the known interacting proteins, MBNL and CUGBP1 have normal roles in 
splicing (Fardaei, Rogers et al. 2002; Kino, Mori et al. 2004; Ho, Bundman et al. 
2005; Warf and Berglund 2007).  The mechanisms regulating the stable RNA 
and the cellular gain of function are complex and are the least understood of the 
nucleotide repeat expansion disorders.   
 
 Molecular mechanisms underlying the myotonic dystrophies 
 Myotonic dystrophy types 1 and 2 (DM1 and DM2) are caused by an 
expansion of different nucleotide repeats within two different genes, and have 
similar, but not identical, clinical manifestations (Ranum and Day 2002; Vihola, 
Bassez et al. 2003; Udd, Meola et al. 2006).  Both diseases display muscle 
weakness, myotonia, progressive muscle wasting, and cataract development.  
Additionally, both diseases show testicular atrophy, insulin sensitivity, and 
sudden cardiac arrythmias and arrest (Ranum and Day 2002; Ranum and 
Cooper 2006; Udd, Meola et al. 2006).  While there are multiple differences 
between the manifestations of DM1 and DM2, the main difference between the 
two diseases is that DM2 does not have a congenital form (Cho and Tapscott 
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2006).  This important difference argues that although the molecular mechanisms 
for the two diseases may be similar, they are not identical.   
 Initially, the proposed mechanism for myotonic dystrophy type 1 was 
thought to be similar to other NREs, like Fragile-X or Huntington’s disease, in that 
the expanded repeat was thought to inhibit DMPK expression or activity.  These 
early studies provided evidence that DMPK mRNA levels were abnormally low 
and the cytoplasmic concentration of the DMPK protein were reduced in adult 
patients with DM1 (Carango, Noble et al. 1993; Fu, Friedman et al. 1993; Krahe, 
Ashizawa et al. 1995).  Mouse models with reduced DMPK levels display adult 
onset myopathy, cardiac conduction defects, and cardiac arrythmias, similar to 
what is seen in DM1 patients (Jansen, Groenen et al. 1996; Reddy, Smith et al. 
1996; Mounsey, Mistry et al. 2000).  Despite the similarities, the symptoms seen 
in DMPK knockout models were thought to be too mild and too focused on only 
the cardiac system to explain the full scope of the myotonic dystrophy disease 
mechanism.   
 The creation of a mouse model for DM1 provided the first clear evidence 
of a possible RNA gain of function mechanism (Mankodi, Logigian et al. 2000; 
Seznec, Agbulut et al. 2001).  A mouse line expressing expanded CTG repeats 
in the 3’UTR of the skeletal actin gene recapitulated most of the symptoms 
associated with DM1 in humans, suggesting that the context of the expansion 
was not necessarily important for disease progression (Mankodi, Logigian et al. 
2000; Seznec, Agbulut et al. 2001).  The DM1 mouse model fit nicely with the 
previous observations that large CUG RNA complexes were found in the nucleus 
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of DM1 patients (Taneja, McCurrach et al. 1995; Taneja 1998).  The presence of 
stable CUG RNA complexes provided an initial clue in to the potential 
mechanism of the disease and led to the identification of two proteins, CUGBP1 
and MBNL, that bound and colocalized with the RNA (Timchenko, Timchenko et 
al. 1996; Miller, Urbinati et al. 2000).   
 CUGBP1 activity was implicated in DM1 disease progression after the 
observation that CUGBP1 is a regulator of alternative splicing of the troponin T 
(TNNT2) mRNA.  Patients with DM1 showed clear misregulation of TNNT2 
splicing associated with increased CUGBP1 activity, suggesting that aberrant 
CUGBP1 regulation caused some of the symptoms of DM1 (Philips, Timchenko 
et al. 1998).  Other misspliced mRNAs with relevance to DM1 symptoms were 
attributed to an increase in CUGBP1 activity (Charlet-B., Savkur et al. 2002; 
Savkur, Philips et al. 2004).  CUGBP1 is activated by initial binding to RNA 
targets containing CUG motifs, similar to the mechanism of PKR activation 
(Timchenko, Timchenko et al. 1996; Philips, Timchenko et al. 1998).     
 As further evidence for an RNA-mediated gain of function in DM1, the 
protein MBNL colocalizes with nuclear CUG RNA foci (Miller, Urbinati et al. 
2000).  MBNL regulates alternative splicing of TNNT2 and chloride channel 1 
(ClC-1) and reduced MBNL activity leads to a failure of these transcripts to 
mature (Kanadia, Johnstone et al. 2003).  Alternative isoforms of TNNT2 and 
CIC-1 have reduced in vivo activity and are thought to underlie the myopathy and 
cardiac transduction defects of DM1.  Interestingly, increased CUGBP1 activity 
opposes the action of MBNL, whose activity is thought to be reduced by CUG 
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repeat RNA binding.  Knockout of MBNL activity in mice gives rise to many of the 
clinical symptoms of DM1, suggesting that a loss of MBNL activity leads to some 
of the symptoms of DM1 (Kanadia, Johnstone et al. 2003).   
 The discovery that a CCTG expansion in the first intron of znf9 causes 
DM2 provided additional support to the RNA-mediated gain of function 
hypothesis for the myotonic dystrophies.  CCUG RNA foci are found in skeletal 
muscle tissue from DM2 patients and show colocalization with MBNL and 
increased CUGBP1 levels (Liquori, Ricker et al. 2001; Margolis, Schoser et al. 
2006; Salisbury, Sakai et al. 2008; Salisbury, Schoser et al. 2009).  Additionally, 
DM2 patients show similar aberrant splicing as patients with DM1, suggesting 
that the two diseases share a similar underlying mechanism.  Despite all of the 
evidence for the RNA-mediated gain of function model, most laboratories have 
ignored or rejected critical evidence supporting a more complex mechanism for 
the myotonic dystrophies. 
 
Evidence for a combined RNA-mediated gain of function and a ZNF9 loss of 
function model 
 
 As previously mentioned, DM1 and DM2 share many clinical symptoms, 
but the main difference between the two diseases is the congenital form of DM1.  
This fact alone argues against a unified mechanism for DM1 and DM2, but the 
additional observed clinical and cellular differences between the two diseases 
suggests that the two diseases have different mechanisms.  The RNA-mediated 
toxicity model explains a large number of DM1 and DM2 features, and certainly 
contributes to myotonic dystrophy pathogenesis.  Neither the CTG expansion 
 22
model nor the MBNL knockout models for myotonic dystrophy manifest a 
congenital form, suggesting that the presence of the repeat expansion in another 
gene or loss of MBNL function are not enough to cause DM1.   
 Knockout of DMPK function in mice leads to myopathy and cardiac 
conduction defects, indicating that DMPK gene activity may be involved in DM1 
disease progression (Jansen, Groenen et al. 1996; Reddy, Smith et al. 1996; 
Mounsey, Mistry et al. 2000).  Expression of 100 CUG repeats within the DMPK 
3’UTR causes severe myoblast differentiation defects, while expression of the 
same repeats within an unrelated 3’UTR has no observable effect on 
differentiation (Amack and Mahadevan 2001; Amack, Reagan et al. 2002).  
These data underscore the importance for the genomic context of the nucleotide 
expansion.   
 Mice homozygous for a loss in znf9 gene function die during embryonic 
development (Chen, Liang et al. 2003).  Approximately 40% of the heterozygous 
animals die shortly after birth with craniofacial and skeletal muscle defects, but 
initial characterization of the other 60% revealed phenotypically normal animals 
(Chen, Liang et al. 2003).  Further examination of supposedly normal znf9+/- 
animals resulted in a striking observation.  znf9+/- animals display late-onset 
muscle weakness, myotonia, cardiac conduction defects, and cataract 
development, symptoms seen in patients with myotonic dystrophy (Chen, Wang 
et al. 2007).  Restoration of ZNF9 protein levels rescued the myotonic dystrophy-
like defects in znf9+/- animals.  These results provided the first clear evidence that 
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the RNA-mediated gain of function model for myotonic dystrophy was not fully 
correct and may need to include a loss of function for either DMPK or ZNF9.   
  
X. Rationale for dissertation research 
 The observation that a loss of ZNF9 gene activity might contribute to the 
pathogenesis of myotonic dystrophy type 2 provided a clear rationale for this 
dissertation.  Previous work in the Link lab suggested that ZNF9 functions as a 
regulator of cap-independent translation (Gerbasi and Link 2007).  I hypothesized 
that if ZNF9 activity contributed to myotonic dystrophy, patients with DM2 would 
have reduced cap-independent translation activity due to a decrease in ZNF9 
function.  The key component to determining if ZNF9 activity is deficient in DM2 
patients is determining the exact molecular function of the ZNF9 protein.     
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CHAPTER II 
 
ZNF9 ACTIVATION OF IRES-MEDIATED TRANSLATION OF THE HUMAN 
ODC MRNA IS DECREASED IN MYOTONIC DYSTROPHY TYPE 2 
 
The following chapter was published in PLoS ONE 5(2): e9301. Feb 2010.   
 
Abstract 
Myotonic dystrophy types 1 and 2 (DM1 and DM2) are forms of muscular 
dystrophy that share similar clinical and molecular manifestations, such as 
myotonia, muscle weakness, cardiac anomalies, cataracts, and the presence of 
defined RNA-containing foci in muscle nuclei.  DM2 is caused by an expansion of 
the tetranucleotide CCTG repeat within the first intron of ZNF9, although the 
mechanism by which the expanded nucleotide repeat causes the debilitating 
symptoms of DM2 is unclear.  Conflicting studies have led to two models for the 
mechanisms leading to the problems associated with DM2.  First, a gain-of-
function disease model hypothesizes that the repeat expansions in the 
transcribed RNA do not directly affect ZNF9 function.  Instead repeat-containing 
RNAs are thought to sequester proteins in the nucleus, causing misregulation of 
normal cellular processes.  In the alternative model, the repeat expansions impair 
ZNF9 function and lead to a decrease in the level of translation.  Here we 
examine the normal in vivo function of ZNF9.  We report that ZNF9 associates 
with actively translating ribosomes and functions as an activator of cap-
independent translation of the human ODC mRNA.  This activity is mediated by 
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direct binding of ZNF9 to the internal ribosome entry site sequence (IRES) within 
the 5’UTR of ODC mRNA.  ZNF9 can activate IRES-mediated translation of ODC 
within primary human myoblasts, and this activity is reduced in myoblasts derived 
from a DM2 patient.  These data identify ZNF9 as a regulator of cap-independent 
translation and indicate that ZNF9 activity may contribute mechanistically to the 
myotonic dystrophy type 2 phenotype.   
 
Introduction 
Myotonic dystrophy types 1 and 2 are forms of muscular dystrophy 
resulting from large expansions of nucleotide repeats within noncoding regions of 
DMPK and ZNF9, respectively (Cho and Tapscott 2007). Myotonic dystrophy 
type 1 (DM1) is caused by expansion of a CTG triplet repeat within the 3’ 
untranslated region (UTR) of DMPK, whereas myotonic dystrophy type 2 (DM2) 
results from expansion of a CCTG repeat within the first intron of ZNF9 
(Aslanidis, Jansen et al. 1992; Liquori, Ricker et al. 2001).  Despite the different 
expansions within two apparently unrelated genes, both diseases share many 
common clinical manifestations, including myotonia, muscle weakness, cataract 
development, insulin resistance, and cardiac conduction defects.  The shared 
symptoms suggest the mechanisms causing the disease may also be shared 
(Ranum and Day 2002; Day, Ricker et al. 2003).  Although they have similar 
symptoms, there are also a number of very dissimilar features making them 
clearly separate diseases (Udd, Meola et al. 2006).  A major difference between 
DM1 and DM2 is that only DM1 shows a congenital form of the disorder (Cho 
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and Tapscott 2007). Other apparent differences are the distribution of clinical 
muscle weakness/atrophy and the morphological involvement of different fiber 
types. In DM1, weakness and atrophy involves distal, facial, bulbar and 
respiratory muscles, whereas in DM2 the proximal muscles are preferentially 
involved, and the patients have marked muscle pains (Ricker, Koch et al. 1994). 
DM1 type 1 fibers show atrophy changes whereas in DM2 a subpopulation of 
type 2 fibers are highly atrophic (Vihola, Bassez et al. 2003). These phenotypic 
differences suggest that other cellular and molecular pathways are involved 
besides the shared molecular pathomechanisms. 
In both DM1 and DM2, the expanded nucleotide repeats are transcribed 
but are not translated.  For ZNF9, the transcribed CCTG repeats within the first 
intron are apparently removed from both the wild-type and DM2 pre-mRNAs by 
splicing, resulting in translation of the normal ZNF9 protein (Margolis, Schoser et 
al. 2006).  Two studies of ZNF9 mRNA and protein expression levels reported no 
change in diseased myoblasts or lymphoblastoid cell lines compared to 
unaffected cells (Botta, Caldarola et al. 2006; Margolis, Schoser et al. 2006).  
These results indicate that the repeat RNA does not affect normal ZNF9 function 
and have led to a disease model in which the expanded repeats somehow 
dominantly interfere with other cellular processes (Amack, Paguio et al. 1999; 
Seznec, Agbulut et al. 2001; Amack, Reagan et al. 2002; Mankodi, Takahashi et 
al. 2002).  This model is supported by the observation that expression of 
transgenically engineered expanded CTG repeats in unrelated genes can cause 
some of the phenotypes seen in the myotonic dystrophies (Mankodi, Logigian et 
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al. 2000).  This toxic-RNA gain-of-function disease model hypothesizes that the 
transcribed CTG or CCTG repeat expansions fold into RNA structures that are 
retained in the nucleus forming distinct foci.  Experimental data shows the 
ribonuclear complexes sequester similar sets of proteins in the nucleus, 
apparently causing misregulation of normal cellular processes, in particular RNA 
splicing (Fardaei, Larkin et al. 2001; Fardaei, Rogers et al. 2002; de Haro, Al-
Ramahi et al. 2006).  Most prominently, the transcribed CTG and CCTG repeats 
both bind muscleblind-like (MBNL) and CUGBP1/ETR-3-like factors (CELF) that 
are involved in alternative RNA splicing. 
In contrast to the toxic-RNA gain-of-function model, several studies have 
revealed a role for ZNF9 in DM2.  Knockout of ZNF9 in mice results in embryonic 
lethality due to defects in forebrain and craniofacial development (Chen, Liang et 
al. 2003).  Other studies in chick and zebrafish show that ZNF9 deletion results in 
severe brain and muscle phenotypes (Abe, Chen et al. 2006; Weiner, Allende et 
al. 2007).  Mice heterozygous for the znf9 knockout display late-onset muscle 
wasting, cardiac abnormalities, cataracts, and mRNA expression defects similar 
to those seen in DM2 (Chen, Wang et al. 2007).  These defects can be rescued 
by reintroduction of wild-type levels of ZNF9, suggesting that a loss of ZNF9 
function likely contributes to DM2.  Similar to DM2, DMPK deficient mice show a 
subset of the phenotypes seen in DM1 patients (Reddy, Smith et al. 1996). A 
recent study reports that expanded CCTG repeats in DM2 give rise to defects in 
ZNF9 expression and cellular localization (Huichalaf, Schoser et al. 2009). The 
discrepancy between this study and earlier characterizations of ZNF9 expression 
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and localization in DM2 cells is unclear.  This study reported that decreased 
ZNF9 activity is linked to a downregulation of translation (Huichalaf, Schoser et 
al. 2009). A second study has reported that the expression of the CCTG repeats 
in mouse and human myoblasts alters translation and protein degradation 
(Salisbury, Schoser et al. 2009). These data support the notion that the ZNF9 
protein may play a role in DM2 and that the RNA-mediated dominant gain-of-
function model for myotonic dystrophy is not the only pathomechanism for the 
disease.   
 The lack of an in vivo biochemical function for ZNF9 has hindered the 
ability to clearly define the role that ZNF9 plays in DM2.  ZNF9 has been 
proposed to act in a variety of cellular functions, including transcription, splicing, 
and translation (Michelotti, Tomonaga et al. 1995; Pellizzoni, Lotti et al. 1997; 
Pellizzoni, Lotti et al. 1998; Chen, Liang et al. 2003; Gerbasi and Link 2007).  
Recent evidence suggests that ZNF9 likely acts as a regulator of translation.  
ZNF9 associates with 5’ terminal oligopyrimidine (TOP) mRNA elements 
(Cardinali, Carissimi et al. 2003), and 5’ TOP mRNAs are inefficiently translated 
in DM2 (Huichalaf, Schoser et al. 2009).  Previously, our group identified ZNF9 
as a positive regulator of IRES-mediated translation for the rat ornithine 
decarboxylase (ODC) mRNA (Gerbasi and Link 2007), providing further evidence 
that ZNF9 functions in translational regulation. 
 We hypothesized that ZNF9 acts as an IRES trans-activating factor (ITAF) 
for cap-independent translation of the human ODC mRNA.  By analyzing the in 
vivo function of ZNF9 as an activator of cap-independent translation, we sought 
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to determine whether a loss in ZNF9 activity contributes to DM2.  The data 
presented here suggest that ZNF9 directly interacts with the IRES of the human 
ODC mRNA, associates with translating ribosomes, and activates cap-
independent translation.  Additionally, our data show that ZNF9 activity is 
reduced in myoblasts from a patient affected with DM2, providing further 
evidence that a loss-of-function mechanism contributes to myotonic dystrophy 
type 2 disease. 
 
Materials and Methods 
Cell Culture  
HEK293T and HeLa cell lines were grown in DMEM containing 10% fetal bovine 
serum and penicillin/streptomycin solution according to standard laboratory 
practices (ATCC).  Control and DM2 human myoblasts were grown in Complete 
Myoblast Medium (Promocell GmbH, Heidelberg, Germany) and cultured 
according to the manufacturer’s recommendations.   DM2 myoblasts were 
established from muscle biopsies from a male patient in his early 40’s with 
clinical symptoms of DM2.  The (CCTG)n repeat size was approximately 4500 
repeats, as determined using established methods (Sallinen, Vihola et al. 2004). 
 
Plasmid Construction 
The full-length 5’UTR of the human ODC mRNA from clone #5088190 (Magic 
Consortium CloneID) was inserted between the Renilla and firefly luciferase 
genes to create pcDNA3.1-hODC-IRES.  pcDNA3.1-V5-ZNF9 was constructed 
 30
by insertion of the PCR-generated full-length open reading frame of human ZNF9 
into pENTR and subsequent recombination into pcDNA3.1/nV5-Dest (Invitrogen) 
by recombinational cloning (Invitrogen).  The PCR primers for cloning ZNF9 were 
5’- CACCATGAGCAGCAATGAGTGCTT-3’ and 5’- 
TTATTAGGCTGTAGCCTCAATTGTGCA-3’.  pcDNA3.1-V5-LacZ was created 
by recombinational cloning of pcDNA3.1/nV5-GW/lacZ into pcDNA3.1/nV5-Dest.   
An HIV –based reporter vector (hODC-IRES) was cloned by introduction of the 
full-length hODC-IRES coding sequence into H163 (Sundrud, Grill et al. 2003).  
pcDNA3.1-hODC-IRES was digested with KpnI and NotI, blunt-ended with 
Klenow fragment, and inserted into the SmaI site of H163.  HIV-ZNF9-myc and 
HIV-LacZ-Myc were created by digestion of pcDNA3.1-ZNF9-myc or pcDNA3.1-
LacZ-myc with KpnI and PmeI.  The fragments were blunt-ended with Klenow 
fragment and inserted into the SmaI site of H163.  All clones were verified by 
DNA sequencing. 
 
Western Blotting 
Rabbit polyclonal antibodies were generated against full-length, recombinant 
ZNF9 (Covance).  Briefly, recombinant human ZNF9 was expressed in E. coli 
(BL21DE3) as an N-terminal GST fusion protein and purified by glutathione 
affinity chromatography.  ZNF9 without the GST tag was released from the 
column by cleavage with 3C protease (Prescission Protease, GE).  The purity 
and identity of ZNF9 were determined by Coomassie staining and mass 
spectrometry analysis.  ZNF9 antibodies were affinity purified against full-length 
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recombinant ZNF9.  Antibodies for immunoblotting were used at the following 
concentrations: ZNF9 (1:1,000), GAPDH (Millipore) (1:5,000), c-myc (Cell 
Signaling) (1:1,000), anti-myc epitope (Vanderbilt Monoclonal Antibody Core) 
(1:2,000), V5 (Invitrogen) (1:2,500).   
 
Subcellular Fractionation 
HeLa cells were transfected with either pcDNA3.1-ZNF9-myc or pcDNA3.1-LacZ-
myc using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
recommendations.  Transfected cells were fractionated into whole cell, 
cytoplasmic, and nuclear fractions using the NE-PER Nuclear and Cytoplasmic 
Extraction reagents (Thermo Scientific) according to the manufacturer’s 
recommendations. 
 
Quantitative RT-PCR 
Total RNA was isolated from cultured cells using TRIzol according to 
manufacturer’s recommendations (Invitrogen).  RNA was quantified using a 
Nanodrop spectrophotometer (Thermo Scientific).  1μg of RNA was DNase-
treated (Promega) and used in reverse transcription reactions primed with 
random hexamers (Superscript III, Invitrogen).  cDNA samples were treated with 
RNase H and 5μL of each sample were used for quantitative real-time PCR 
reactions.  Real-time PCR was performed using the Applied Biosystems 7000 
and the manufacturer’s protocols (Applied Biosystems). Taqman probes used 
were: ZNF9 (Hs00231535_m1) and GAPDH (4333764T). 
 32
Sucrose Gradient Analysis and Centrifugation 
Polysome analysis was performed as previously described (Gerbasi and Link 
2007).  Intact cells were lysed by repeated vortexing in five pellet volumes of lysis 
buffer (100 mM Tris, 10 mM MgCl2, 100 mM KCl, and 1% TritonX-100), and 
cellular debris was removed by centrifugation (4°C, 13,500xg). 10 O.D. units of 
lysate were loaded onto a 7-47% sucrose gradient.  Unless indicated, sucrose 
solutions contained 10 mM Tris-HCl (pH 7.5), 5% cycloheximide, 5 mM MgCl2, 
and 100 mM EDTA.  Gradients were centrifuged for 2 h at 178,000xg in a Sorvall 
SW-41 swinging bucket rotor.  Polysome analysis was performed by bottom 
displacement and monitored by UV absorbance at 254 nm. Fractions were 
collected for western blotting.  Ribosome pelleting experiments were performed 
by centrifugation of the cell lysates described above through a 1 M sucrose 
cushion (-/+ 50 mM EDTA) at 100,000xg for 2 h in a TLA120.2 rotor.  The 
resulting ribosome pellets were resuspended in ribosome solubilization buffer (20 
mM TRIS pH 7.5, 5 mM MgCl2, 6 M urea).  Supernatant fractions were 
precipitated with trichloroacetic acid, washed with acetone, and resuspended in 
ribosome solubilization buffer.  For ribosome salt wash analysis, ribosome pellets 
were isolated as described above, and the supernatants were discarded.  Pellets 
were washed in ice cold PBS and resuspended in ribosome salt wash buffer 
containing 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM BME, and either 100 
mM, 250 mM, 500 mM, or 1 M potassium acetate.  Resuspended ribosomes 
were then centrifuged at 100,000xg for 2 h in a TLA120.2 rotor.  Supernatant 
fractions were removed and TCA precipitated as described above, and pellet 
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fractions were resuspended in solubilization buffer.  Equal volumes of lysate 
were separated by polyacrylamide gel electrophoresis, transferred to 
nitrocellulose membranes, and immunoblotted for ZNF9 protein. 
  
In vitro RNA Synthesis and Binding Assays 
RNA probes were synthesized using double-stranded DNA templates with 
upstream T7 promoters using Ambion’s MegaShortScript kit according to the 
manufacturer’s recommendations.  The DNA primers used were:  
5’-TAA TAC GAC TCA CTA TAG G-3’ and 5’-GAT TTC TTG ATG TTC CTA 
TGG AAA ACT AAG AGA TGG AAT TGA AAG AAA CCT ATA GTG AGT CGT 
ATT A-3’.  The sequence of the synthesized RNA probe is 5’-
UUUCUUUCAAUUCCAUCUCUUAGUUUUCCAUAGGAACAUCAAGAAAUC-3’. 
The RNA probe was purified by TRIzol extraction (Invitrogen), and the size and 
purity were determined by gel electrophoresis.  Probes were end labeled with 32P 
using T4 polynucleotide kinase according to the manufacturer’s 
recommendations (NEB).  All RNA binding reactions were performed with 20 
pmol of labeled RNA in a reaction volume of 30 μL of RNA binding buffer (150 
mM NaCl, 100 mM NaHPO4, and 5% glycerol) in a clear-bottom 96 well plate at 
room temperature, unless otherwise indicated.  UV cross-linking reactions were 
performed on a 302 nm UV lightbox for 5 min at room temperature.  Reactions 
were stopped by addition of Laemmli buffer.  The reactions were analyzed by 
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes.  
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Membranes were stained with Ponceau S to measure ZNF9 protein levels, and 
exposed to film for imaging of the radioactive signals.    
 
Luciferase Reporter Assays 
HeLa cells were grown in 24-well plates to 70% confluence and transfected with 
the human ODC-IRES reporter and either pcDNA3.1-V5-LacZ or pcDNA3.1-V5-
ZNF9 using Lipofectamine 2000 according to manufacturer’s recommendations 
(Invitrogen).  Cells were harvested after 24 h, and dual luciferase reporter assays 
were performed according to the manufacturer’s recommendations (Promega) 
using a Turner TD-20/20 lumninometer.   
 
Mass Spectrometry-based Proteomics 
Sample preparation and mass spectrometry-based proteomics analysis were 
performed as described earlier (Fleischer, Weaver et al. 2006; Gerbasi and Link 
2007). 
 
Generation of shRNA Virus 
Double-stranded DNA sequences were generated and cloned into pENTR/U6 
using the Block-iT U6 RNAi Entry vector kit (Invitrogen). Primer sequences were 
ZNF9-198 Top strand 5’- CAC CGC AGC AAT GAG TGC TTC AAG TAG AGC 
TTG ACT TGA AGC ACT CAT TGC TGC -3’, ZNF9-198 Bottom strand 5’-AAA 
AGC AGC AAT GAG TGC TTC AAG TCA AGC TCT ACT TGA AGC ACT CAT 
TGC TGC -3’, ZNF9-645 Top Strand 5’-CAC CGC AAG ACA AGT GAA GTC 
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AAC TAG AGC TTG AGT TGA CTT CAC TTG TCT TGC -3’, ZNF9-645 Bottom 
Strand 5’-AAA AGC AAG ACA AGT GAA GTC AAC TCA AGC TCT AGT TGA 
CTT CAC TTG TCT TGC -3’.  Ligation products were transformed into One Shot 
TOP10 competent E. coli (Invitrogen). Minipreps were performed on selected 
colonies and shRNA fidelity was verified by DNA sequencing. Gateway 
recombination reactions were performed by transfering the shRNA constructs into 
the lentiviral vector system as described previously (Antons, Wang et al. 2008).  
Lentiviruses encoding ZNF9 or control shRNAs were generated by calcium-
phosphate mediated co-transfection of HEK293T cells with the resulting shRNA-
containing lentiviral vector, VSV-G, and pol/gag.  VSV-G and pol/gag vectors 
were kind gifts of Dr. D. Unutmaz, NYU School of Medicine (Motsinger, Haas et 
al. 2002).  The resulting viral supernatants were concentrated using Amicon 100K 
cut-off concentrators (Millipore).   
 
Viral Infection and Knockdown of ZNF9 
Viral supernatants were applied to 1x106 HeLa cells cultured under standard 
conditions.  Infections were performed at an MOI of 2 and were allowed to 
proceed for 48 h.  GFP+ cells were sorted and collected using a FACSAria flow 
sorter (BD Biosciences) and placed back in culture.  Knockdown of target genes 
was assessed by quantitative RT-PCR (Taqman) and western blotting directed at 
the target protein.   
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Infection of Primary Myoblasts 
HIV-hODC-IRES reporter, HIV-ZNF9-myc, and HIV-LacZ-myc viral supernatants 
were generated by calcium phosphate mediated co-transfection of the HIV vector 
and pL-VSV-G into HEK293T cells cultured in DMEM with 10% FBS (Sundrud, 
Grill et al. 2003).  The medium was changed after 6 h and replaced with myoblast 
complete growth medium.  Supernatants were collected 48 h after transfection 
and were sterile filtered and stored at -80°C.  Primary myoblasts were seeded at 
15,000 cells per well in myoblast complete growth medium.  Viral supernatants 
were added to the cells for 8 h, the medium was changed to standard growth 
medium, and the cells were subsequently assayed after 48 h for luciferase 
activity as described above.    
 
Statistical Methods 
Two-tailed Student’s T-tests (95% confidence interval) were performed on 
pairwise combinations of data to determine statistical significance.  
 
Results 
ZNF9 specifically binds to a cellular mRNA IRES element   
 Previously, we identified ZNF9 in a screen for proteins binding to an IRES 
element from the rat ornithine decarboxylase (ODC) mRNA (Pyronnet, Pradayrol 
et al. 2000; Gerbasi and Link 2007). It was unknown whether ZNF9 directly binds 
the ODC’s IRES RNA sequence or if it binds in the presence of other protein 
cofactors.  We tested whether ZNF9 can bind directly to a 45 bp region in the 
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human ODC mRNA corresponding to the rat IRES-containing sequence.  In 
Figure 1A, we show that ZNF9 directly binds to the 45 bp human ODC IRES 
RNA sequence.  The interaction is sequence specific since the interaction was 
abolished with the addition of a 50-fold molar excess of an unlabeled competitor 
identical to the probe (Fig. 1).  In contrast, the addition of a 50-fold molar excess 
of a non-specific competitor RNA did not reduce or eliminate ZNF9 binding to the 
ODC IRES RNA probe (Fig. 1).  The ability of ZNF9 to bind to a putative IRES 
element in the absence of other proteins suggests that it may act as an ITAF 
through direct recognition of the IRES sequence.  One possible mechanism for 
ITAF function involves ZNF9 acting as a physical scaffold between an IRES-
containing mRNA and the ribosomal machinery.  Tethering of the mRNA to the 
ribosome by an ITAF is thought to facilitate translation of the mRNA (Stoneley 
and Willis 2004; Spriggs, Bushell et al. 2005; Semler and Waterman 2008).  In 
order to test this model for ZNF9, we investigated the interactions of ZNF9 with 
the translation machinery. 
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FIGURE 1 
 
 
 
Figure 1. ZNF9 specifically binds to a human cellular mRNA IRES 
element.  A.  Increasing amounts of recombinant, full-length ZNF9 were 
incubated with 32P-end-labeled ODC RNA probe and cross-linked. 
Reactions were separated by polyacrylamide gel electrophoresis, 
transferred to nitrocellulose and exposed to X-ray film.  Membranes were 
stained for ZNF9 protein using Ponceau S.  B.  Recombinant ZNF9 was 
incubated with 32P-end-labeled ODC RNA probe and either a 50-fold molar 
excess of bovine liver tRNA or a 50-fold molar excess of unlabeled ODC 
RNA competitor (comp) probe.  Samples were processed as in A.   
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ZNF9 interacts with the translating eukaryotic ribosome 
Based on its proposed role as an ITAF for cap-independent translation, we 
hypothesized that ZNF9 interacts with translating ribosomes.  Previous work from 
our lab showed that ZNF9 co-sediments with the polyribosome fractions, 
suggesting an interaction with the ribosome and a role in translation (Gerbasi and 
Link 2007).  Therefore, we sought to analyze the intracellular localization of ZNF9 
and whether ZNF9 associates with the ribosome during active translation.  
Subcellular fractionation experiments revealed that the majority of ZNF9 protein 
is found in the cytoplasm (Fig. 2A).  Both myc-tagged and endogenous ZNF9 
localize to the cytoplasm (Fig. 2A). Western blotting for a known nuclear protein 
(c-myc) and a cytoplasmic protein (β-galactosidase) were used as controls for 
the selectivity of the fractionation technique.  Both control proteins were found 
exclusively in the expected fraction.  A small amount (~ 5%) of the total ZNF9 
found in the cell was localized to the nucleus.  While this may be carryover from 
the cytoplasmic fraction, the experimental and control results suggest that a 
small fraction of ZNF9 is nuclear.  The significance and function of nuclear ZNF9 
are unknown, but ZNF9 has been shown previously to have a nuclear pool 
(Huichalaf, Schoser et al. 2009; Salisbury, Schoser et al. 2009).  The cytoplasmic 
localization of ZNF9 is consistent with its proposed role in translation.   
Differential centrifugation of high molecular weight complexes is a well-
established technique for the isolation of polyribosomes (Merrick 1979).  To 
determine if ZNF9 copurifies with human polysomes, lysates from HeLa cells 
were loaded onto a sucrose cushion and the polyribosome fraction was isolated. 
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The majority of ZNF9 is found in the pellet (polyribosome) fraction, which 
suggests that ZNF9 associates with translating ribosomes (Fig. 2B).  A fraction of 
ZNF9 protein remains in the supernatant, suggesting that a portion of ZNF9 
protein is not actively engaged with the ribosome (Fig. 2B).  As a control, 
GAPDH, a protein that does not interact with translating ribosomes, is absent 
from the pellet fraction and is exclusively localized to the supernatant.  The 
addition of EDTA disrupts polyribosome formation and is often used as a control 
to rule out association with other high molecular weight complexes that co-
sediment with ribosomes (Fleischer, Weaver et al. 2006).  In the presence of 
EDTA, ZNF9 is found exclusively in the supernatant fraction (Fig. 2B), suggesting 
that the ZNF9 sedimentation in the absence of EDTA is due to an association 
with the ribosome and not a separate protein complex.  We also analyzed ZNF9 
sedimentation with ribosomes by linear sucrose gradient ultracentrifugation and 
confirmed that ZNF9 associates with very high molecular weight particles and 
that this interaction is abolished by the addition of EDTA (Fig. 2C).  As seen 
previously, a fraction of ZNF9 does not sediment in the ribosome-containing 
fractions, suggesting that a pool of ZNF9 is not actively engaged in translation.  
In order to further test our hypothesis that ZNF9 acts as a translation 
initiation factor for cap-independent translation, we sought to test how tightly 
ZNF9 is associated with ribosomal proteins.  Ribosome salt wash experiments 
are often used to separate core ribosomal protein subunits from associated 
translation factors (Link, Fleischer et al. 2005).  The assay is also used to 
estimate the relative strength of protein-ribosome interactions by increasing the 
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salt concentration (Link, Eng et al. 1999).   We hypothesized that, like other 
translation factors, ZNF9 would be released from the polysomes with 
intermediate concentrations of salt.  At low concentrations of potassium acetate, 
ZNF9 localizes exclusively to the ribosome pellet (Fig. 2D). At 500mM potassium 
acetate, a concentration that is sufficient to strip most translation factors from 
ribosomes (Merrick 1979), ZNF9 is partially dissociated from the ribosome.  At 1 
M potassium acetate, ZNF9 protein is completely removed from the ribosome, 
suggesting that ZNF9-ribosome interactions are not as strong as the core 
ribosomal subunits.  In summary, our data indicate that ZNF9 associates with 
translating polysomes and that the strength and mode of the interaction is 
consistent with those of other translation factors (Merrick 1979; Fleischer, 
Weaver et al. 2006).     
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FIGURE 2 
 
 
 
Figure 2. ZNF9 interacts with the translating human eukaryotic ribosome.  A. 
Western blots of subcellular fractions of HeLa cells extracts transfected with either 
ZNF9-myc or LacZ-myc and probed with the indicated antibodies.  10% of each 
fraction was analyzed by western blotting.  WCL: whole cell extract, C: cytoplasmic, 
N: nuclear   B. ZNF9 and GAPDH western blotting of supernatant and polysome 
fractions of HeLa cell lysates isolated in the absence or presence of EDTA. 
Quantification was normalized to the levels of ZNF9 in the supernatant fraction in the 
absence of EDTA  C.  ZNF9 western blotting of sucrose gradient fractions of HeLa 
cell lysates in the absence or presence of EDTA.  Equal cell lysate amounts (10 O.D.
units) were applied to each gradient (-/+ 50 mM EDTA), and each fraction was TCA 
precipitated.  50% of the total precipitated protein was analyzed by western blotting. 
D.  ZNF9 western blotting analysis of supernatant and pellet fractions from ribosome 
salt wash experiments.  Western blots were quantified and the data are reported as 
ratios of ZNF9 in the pellet fraction to the amount of ZNF9 in the supernatant, 
normalized to the values for 100 mM potassium acetate.   
 43
ZNF9 activates cap-independent translation of the human ODC mRNA 
We have determined that ZNF9 binds specifically to the 5’UTR of the 
human ODC mRNA and interacts with translating ribosomes.  Previous data from 
our lab revealed that ZNF9 can activate cap-independent translation of the rat 
ODC mRNA, which is similar, but not identical, to the human ODC mRNA.  
These data suggest a direct role for ZNF9 in regulating translation of the ODC 
mRNA. To test if ZNF9 promotes human ODC IRES activity,  a bicistronic 
reporter plasmid with the full-length human ODC 5’UTR was used to test the 
ability of ZNF9 to activate cap-independent translation (Fig. 3A).  Overexpression 
of ZNF9 in HeLa cells resulted in an ∼3-fold increase (p-value=0.0031) in 
translation of the second cistron of the reporter compared to control experiments 
with β-galactosidase overexpression (Fig. 3B).  These data, along with a 
demonstration of direct ZNF9 binding to the 5’UTR of ODC, strongly suggests 
that ZNF9 acts as a translation factor for cap-independent translation of the 
human ODC mRNA.   
In order to validate the role for ZNF9 in cap-independent translation of the 
human ODC mRNA, we designed specific short hairpin RNA constructs 
(shRNAs) to knockdown expression of ZNF9 mRNA.  The short hairpin 
constructs were expressed in a lentiviral system for infection into HeLa cells, and 
infected cells were selected for stable GFP expression by flow cytometry.  Cells 
expressing the ZNF9-specific shRNA showed ∼90% reductions (p-value=2.2x10-
5) in ZNF9 mRNA levels and a reduction in ZNF9 protein levels compared to 
control shRNA-expressing cells, as assessed by quantitative RT-PCR and 
 44
western blotting (Fig. 3C and insert).  These cells with dramatically reduced 
levels of ZNF9 have ∼30% reduction (p-value=0.0014) in cap-independent 
translation of ODC (Fig. 3D), suggesting that ZNF9 is required for full activation 
of cap-independent translation of the ODC mRNA.    
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FIGURE 3 
 
Figure 3. ZNF9 activates cap independent-translation of the human ODC mRNA.  A. 
Diagram of the ODC bicistronic vector for measuring cap-independent translation of human 
ODC.  5’meG: 5’-methyl-G cap structure.  B.  HeLa cells expressing the ODC bicistronic 
vector and either V5-ZNF9 or V5-LacZ were analyzed for luciferase activity.  The level of 
cap-independent translation is reported as a ratio of cap-independent translation (firefly) to 
cap-dependent translation (Renilla).  Values are averages of 6 independent experiments. 
The error bars are the standard error of the mean (S.E.M). The insert figure is a 
representative western blot analysis showing the V5-LacZ and V5-ZNF9 levels in the HeLa 
cells lysates.  C. ZNF9 mRNA and protein levels after RNAi of ZNF9 in HeLa cells.  HeLa 
cells expressing either a control shRNA or a ZNF9-specific shRNA were analyzed using 
quantitative RT-PCR and western blotting to quantify expression of ZNF9 RNA and protein, 
respectively.  The RT-PCR values were computed using the ΔΔCt method and are 
normalized to the levels of GAPDH mRNA.  Error bars represent the standard error.  The 
insert figure is a western blot showing the ZNF9 proteins levels.  Recombinant ZNF9 
(rZNF9) was used as a positive control, and equal amounts of protein were loaded in each 
lane as assessed by BCA protein assays. D.  HeLa cells expressing the ODC bicistronic 
vector and either a control or ZNF9-specific shRNA were assessed for luciferase activity. 
The level of cap-independent translation is reported as a ratio of cap-independent 
translation (firefly) to cap-dependent translation (Renilla).   Values are the averages of 3 
independent experiments and are normalized to the control shRNA.  The error bars are the 
S.E.M.    
 46
Cap-independent translation of ODC is defective in human DM2 myoblasts 
Our data show that ZNF9 stimulates the cap-independent translation of 
the ODC mRNA.  Using a biochemical assay for ZNF9 function, we sought to 
address the critical question of whether the repeat expansions that cause human 
DM2 also compromise this function of ZNF9.  If ZNF9 activity is reduced in DM2, 
we predicted that translation of the ODC mRNA would be reduced compared to 
wild-type myoblasts.  A bicistronic reporter (HIV-hODC) for cap-independent 
translation of ODC was introduced into normal and primary human DM2 
myoblasts by viral infection.  We found cap-independent activation of ODC 
function is reduced in DM2 (Fig. 4A).  DM2 myoblasts show a 31% reduction (p-
value=0.003) in cap-independent translation of the ODC reporter (Fig. 4A), 
providing evidence that cap-independent translation is reduced in DM2.  Using 
quantitative RT-PCR for ZNF9, we determined that the DM2 myoblasts used in 
our analysis have ∼ 50% of the ZNF9 mRNA (p-value=0.0003) found in wild-type 
myoblasts (Fig. 4B), similar to what was observed in an earlier study (Huichalaf, 
Schoser et al. 2009).  
To test if the reduction in cap-independent translation results from loss of 
ZNF9 activity, we tested whether overexpression of ZNF9 would rescue the 
defect.  We overexpressed ZNF9 or β-galactosidase in wild-type and DM2 
myoblasts by infection with HIV-based virions.  Overexpression of ZNF9 in wild-
type myoblasts increased cap-independent translation 59% (p-value=0.0016) as 
seen previously in the HeLa cell lines (Fig. 3B).  Expression of β-galactosidase 
(LacZ) in WT and DM2 myoblasts had no discernible effect on cap-independent 
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translation, as expected from the results shown in Figure 4A.  Overexpression of 
ZNF9 in DM2 myoblasts results in a 12% increase (p-value=0.235) in cap-
independent translation of the ODC reporter compared to DM2 myoblast controls 
(Fig. 4C). The level of cap-independent translation in ZNF9-overexpressing DM2 
myoblasts is not restored to the level of wild-type myoblasts (Fig. 4C).  The 
results show that ZNF9 overexpression increases cap-independent translation in 
both wild-type and DM2 myoblasts, but ZNF9 overxpression in DM2 myoblasts is 
not sufficient to restore cap-independent translation of the ODC reporter to the 
level seen in wild-type myoblasts. 
 In summary, our experiments indicate that ZNF9 associates with actively 
translating polysomes and activates cap-independent translation of ODC in 
cultured cell lines.  ZNF9 activates cap-independent translation in primary human 
myoblasts, and this activity is reduced in myoblasts from a DM2 patient.  
Overexpression of ZNF9 partially restores cap-independent translation in human 
DM2 myoblasts (Fig. 4C), suggesting that the repeat expansions causing DM2 
probably contribute to the reduction of at least one aspect of ZNF9 function. 
However, other modes of regulating gene expression may be involved and 
cannot be ruled out. 
 48
 
Figure 4. Cap-independent translation of ODC is defective in DM2 myoblasts.  
A.  IRES activity in wild-type and DM2 myoblast.  Equal numbers of human wild-type or DM2 
myoblasts were infected with virions expressing the bicistronic ODC reporter vector and were 
analyzed for luciferase activity.  The level of cap-independent translation is reported as a ratio 
of cap-independent translation (firefly) to cap-dependent translation (Renilla).   Values are 
averages of 6 independent experiments and are normalized to IRES activity in wild-type 
myoblasts.  B. Differences in ZNF9 mRNA expression in wild-type and DM2 myoblasts. 
Quantitative real-time PCR was performed on equal amounts of total mRNA from wild-type 
and DM2 myoblasts.  Values were computed using the ΔΔCt method and are normalized to 
levels of GAPDH mRNA.  Error bars represent the S.E.M.  C.  IRES activity in wild-type and 
DM2 myoblast overexpressing ZNF9.  Equal numbers of wild-type or DM2 myoblasts were 
infected with the bicistronic ODC reporter vector and vectors for either the overexpression of 
LacZ or ZNF9.  Cell lysates were analyzed for luciferase activity as described above.  Values 
are reported as a ratio of cap-independent translation to cap-dependent translation and are 
representative of 4 independent experiments.  The values are normalized to the value of IRES 
activation in wild-type myoblasts overexpressing LacZ.  Error bars represent the S.E.M.  
 
FIGURE 4 
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Discussion 
Misregulation of translational control is a common cause of multiple 
diseases, including many cancers, fragile X syndrome, and vanishing white 
matter disease (Holland, Sonenberg et al. 2004; Bagni and Greenough 2005; 
Scheper, Proud et al. 2006; Sonenberg and Hinnebusch 2009).  Defects in cap-
independent translation have been shown previously to be linked to diseases 
such as X-linked dyskeratosis congenita (Yoon, Peng et al. 2006), suggesting 
that defects specifically in cap-independent translation can result in human 
diseases.  Previous investigations into ZNF9 activity showed that reduced ZNF9 
protein expression results in diminished translational activity and leads to 
symptoms that mimic those seen in myotonic dystrophy type 2 (Chen, Wang et 
al. 2007; Huichalaf, Schoser et al. 2009; Salisbury, Schoser et al. 2009).   
Our results support a model in which ZNF9 acts as an IRES trans-
activating factor (ITAF) for cap-independent translation of ODC.  ZNF9 binds 
directly to the 5’UTR of the ODC mRNA.  ZNF9 is localized mainly to the 
cytoplasm and physically associates with actively translating ribosomes.  
Overexpression of ZNF9 activates cap-independent translation of a reporter 
construct in tissue culture cells.  This ITAF activity is reduced in primary 
myoblasts from a myotonic dystrophy type 2 patient. These results are consistent 
with a model in which ZNF9 activity is reduced in DM2 patients. 
Because ZNF9 interacts with both an mRNA and ribosomes, one likely  
mechanism for its ITAF activity is recognizing specific IRES sequences or 
structures within the 5’UTR of mRNAs and subsequently recruiting other initiation 
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factors and the ribosome for translation activation (Stoneley and Willis 2004; 
Spriggs, Bushell et al. 2005; Semler and Waterman 2008).  It is unknown 
whether ZNF9 directly recruits the translation machinery or whether other factors 
are required.  Both PCBP2 and La, known ITAFs, have been previously shown to 
interact with ZNF9 and similar RNA substrates (Pellizzoni, Lotti et al. 1997; 
Pellizzoni, Lotti et al. 1998; Crosio, Boyl et al. 2000; Gerbasi and Link 2007).  
Interestingly, ZNF9 was found to interact with an assortment of single-strand 
RNA binding proteins and ribosomal protein subunits in a large-scale proteomic 
screen, consistent with the possibility that ZNF9 acts in concert with other 
proteins to activate translation (Ewing, Chu et al. 2007).  Further examination of 
the interactions of ZNF9 with mRNAs and specific translation proteins will be 
important in elucidating the details of ribosome recruitment during cap-
independent translation, currently a poorly understood process.    
The two conflicting models for the cause of DM2 symptoms stem in part 
from conflicting data regarding the expression of ZNF9 mRNA and protein.  Two 
separate studies noted no change in ZNF9 mRNA and protein levels in DM2 
myoblasts or lymphoblastoid cell lines (Botta, Caldarola et al. 2006; Margolis, 
Schoser et al. 2006).  These results support the prevailing toxic-RNA gain-of-
function disease model in which the repeat expansions do not reduce ZNF9 
activity but rather interfere with other critical processes.  In contrast, Huichalaf et 
al. used both western blotting and in situ antibody staining in DM2 myoblasts to 
detect a decrease in ZNF9 protein levels that correlated with decreased 
translational activity (Huichalaf, Schoser et al. 2009).  These results are 
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consistent with the loss-of-function disease model, in which the repeat 
expansions compromise ZNF9 function.  The discrepancies may be due to low 
sample numbers, the use of unaffected tissue types (lymphoblastoid), or 
differences in the cell line’s genetic backgrounds.  A larger and more 
comprehensive analysis of ZNF9 protein levels in DM2 is warranted to resolve 
the discrepancies.   
Our study of ZNF9 overexpression in DM2 myoblasts suggests that 
neither of the two models completely describes the situation in DM2.  First, we 
find cap-independent translation is reduced but not eliminated in myoblasts from 
DM2 patients compared to myoblasts from healthy controls, a result expected 
from loss of ZNF9 function.  The residual activity in DM2 myoblasts may stem 
from either low levels of ZNF9, partially active ZNF9, or ZNF9-independent 
activity.  Overexpression of ZNF9 in normal myoblasts results in an increase in 
cap-independent translation.  Thus, it seems reasonable to expect that 
overexpression of ZNF9 in DM2 myoblasts would restore cap-independent 
translation to at least normal levels.  Cap-independent translation activity was 
slightly increased compared to control DM2 myoblasts and did not restore wild-
type levels.  This result suggests that activation of cap-independent translation by 
ZNF9 is somehow blocked in DM2 cells, possibly through a dominant-negative 
action of the expanded repeat RNA.  Cell-free, reconstituted system in which 
ZNF9 levels can be carefully controlled will be important for a clearer 
understanding of this phenomenon.  
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Our data presented here and previous observations suggest that a combination 
of an RNA-mediated dominant effect and ZNF9 loss-of-function contribute to 
DM2.  Salisbury et al. have shown that transcribed CCTG repeats are found in 
both the nucleus and the cytoplasm of DM2 myoblasts and that the RNA repeats 
misregulate translation (Huichalaf, Schoser et al. 2009; Salisbury, Schoser et al. 
2009).  ZNF9 may be inhibited by the presence of transcribed CCTG repeats in 
the cytoplasm, much as the RNA splicing factor MBNL activity is thought to be 
inhibited by the presence of transcribed CTG and CCTG RNA in the nucleus 
(Fardaei, Rogers et al. 2002; Warf and Berglund 2007; Yuan, Compton et al. 
2007).  Both proteins contain multiple zinc finger motifs to mediate binding to 
specific RNAs and may be inhibited by similar substrates.  In future work, it will 
be important to determine whether ZNF9 and other RNA binding proteins are 
inhibited by the presence of transcribed CCTG repeats in either the nucleus or 
the cytoplasm. 
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CHAPTER III 
 
SACCHAROMYCES CEREVISIAE GIS2 INTERACTS WITH THE 
EUKARYOTIC TRANSLATION MACHINERY AND IS ORTHOLOGOUS TO 
MAMMALIAN ZNF9 
 
 
Abstract 
The myotonic dystrophy type 2 (DM2) protein ZNF9 is a small nucleic acid 
binding protein proposed to act as a regulator of transcription and translation. 
The precise functions and activity of this protein are poorly understood.  Previous 
work described in Chapter II suggested that ZNF9 facilitates the process of cap-
independent translation through interactions with mRNA and the translating 
ribosome.  To determine the role played by ZNF9 in the activation of this 
specialized form of translation initiation, I aimed to combine genetic and 
biochemical analysis of a putative ZNF9 ortholog, Gis2, in Saccharomyces 
cerevisiae.  Purification of the Gis2p protein followed by mass spectrometry 
based-proteomic analysis identified a large number of co-purifying ribosomal 
subunits and translation factors, strongly suggesting that Gis2p interacts with the 
protein translation machinery.  Polysome profiling and ribosome isolation 
experiments confirm that Gis2p physically interacts with the translating ribosome. 
Interestingly, expression of yeast Gis2p in HEK293T cells activates cap-
independent translation driven by the 5’UTR of the ODC gene. These data 
suggest that Gis2 is functionally orthologous to ZNF9 and may act as a cap-
independent translation factor. Genetic analysis of Gis2p function in 
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Saccharomyces cerevisiae can provide insight into the molecular mechanism of 
the mammalian ZNF9 protein.   
 
Introduction 
The study of human pathologies and disease states are complicated by 
the complexity of human biology.  This is especially true when dealing with 
human genetic disorders that can result from the loss of a single gene’s function, 
like in cystic fibrosis, or through a combination of multiple genetic changes, like in 
cancer and neurological disorders.  Therefore, researchers often seek to study 
related cellular processes in more genetically tractable systems, such as 
Saccharomyces cerevisiae.  In fact, the use of systems such as S. cerevisiae has 
led to a much greater understanding of quite a few uniquely human disease 
states, such as Diamond Blackfan anemia, Parkinson’s disease, cancer, and 
amyotrophic lateral sclerosis (Xu, Pin et al. 2004; Leger-Silvestre, Caffrey et al. 
2005; Cooper, Gitler et al. 2006; Gitler, Bevis et al. 2008; Hemphill, Bruun et al. 
2008; Johnson, McCaffery et al. 2008).   
The human disease myotonic dystrophy type 2 (DM2) is caused by a 
tetranucleotide repeat expansion in the first intron of the znf9 gene, which codes 
for the protein ZNF9.  ZNF9 is a small nucleic acid binding protein believed to 
function as a regulator of either transcription or translation, and has been 
proposed to act as a regulator of cellular growth and proliferation in vertebrates.  
Much of the ambiguity in the reported functions of ZNF9 comes from the 
complexity in studying essential genes in mammalian model systems.  Deletion 
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or mutation of ZNF9 results in embryonic lethality in mice and chickens.  While 
this provides evidence for the importance of the ZNF9 protein in growth and 
development, it does not illuminate the in vivo cellular functions and interactions 
of the protein.   
Recently, we discovered that ZNF9 functions as a regulator of a cap-
independent, or internal ribosome entry site (IRES)-dependent, translation 
(Sammons, Antons et al. 2010).  IRES-mediated translation in eukaryotes is 
mediated by a number of factors, including IRES-specific trans-activating factors 
(ITAFs) that are thought to act through stabilize certain mRNA structures and 
facilitate interactions with the ribosome.  ZNF9 directly binds to the IRES 
sequence in the 5’UTR of the ornithine decarboxylase (ODC) mRNA and 
facilitates the translation of this mRNA independent of the cap complex 
(Sammons, Antons et al. 2010).  Other groups have also observed that ZNF9 
acts as a regulator of translation (Pellizzoni, Lotti et al. 1997; Pellizzoni, Lotti et 
al. 1998; Crosio, Boyl et al. 2000; Schlatter and Fussenegger 2003; Huichalaf, 
Schoser et al. 2009), but the full scope of ZNF9’s cellular interactions and any 
other processes regulated ZNF9 are not well understood.  The use of other 
model systems and lines of inquiry are required to gain a full understanding of 
ZNF9 function.       
Previous studies in the zebrafish, mouse, and chick model systems have 
provided insight into the molecular function of the ZNF9 protein.  ZNF9 mRNA is 
present in the developing embryos of mice, chickens, and zebrafish, with the 
highest level expression being found in regions that will develop into craniofacial 
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structures.  In mice, homozygous znf9 null mutants exhibit embryonic lethality 
due to abnormalities in the developing craniofacial system and developing brain.  
Mice heterozygous for znf9 develop various symptoms, including muscle 
weakness and sudden arrhythmia, which mimic the symptoms of DM2.  
Knockdown experiments in chicks, zebrafish, and Xenopus confirmed that loss of 
ZNF9 activity leads to craniofacial and brain development phenotypes.  Further 
studies in these model systems suggest that ZNF9 regulates cell proliferation or 
apoptosis, although the mechanism of action in these processes is unknown and 
unexplored.     
  The translation machinery of the baker’s yeast Saccharoymces 
cerevisiae and other single-celled eukaryotes is well conserved.  Yeast offers 
many advantages to vertebrate model systems for the genetic study of individual 
proteins or genetic pathways.  Genes required for cell viability, such as many 
eukaryotic translation initiation factors and ribosomal proteins, can still be 
genetically perturbed, allowing for sophisticated gene replacement studies.  The 
S. cerevisiae genome encodes one putative homolog of mammalian ZNF9 called 
Gis2p.  GIS2 was initially cloned as a multi-copy suppressor of the Gal- 
phenotype exhibited by snf1/mig1/srb8 mutants, but no other evidence for Gis2p 
function has been reported.  SNF1, a homolog of human AMPK, is part of a 
signaling cascade that regulates the transcriptional activation of the genes 
required for galactose utilization.  SNF1 is a kinase and phosphorylates MIG1, a 
DNA-binding protein that represses transcription of galactose genes (Ostling and 
Ronne 1998; Treitel, Kuchin et al. 1998).  Phosphyorylated MIG1 is inactive and 
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depresses transcription or the GAL genes, controlled in part by SRB8, a 
component of the Mediator complex (Ostling and Ronne 1998; Treitel, Kuchin et 
al. 1998).  Deletion of MIG1 allows for growth on galactose, but deletion of SRB8 
in mig1 cells creates Gal- cells (Balciunas and Ronne 1995; Balciunas and 
Ronne 1999).  While GIS2 may in fact function to regulate the expression of the 
genes required for galactose utilization, the result has never been replicated or 
followed-up.    
In this study, we show that the S. cerevisiae protein Gis2p shares 
considerable sequence homology with the mammalian ZNF9 protein and is likely 
a functional ortholog.  Gis2p associates with translating ribosomes and copurifies 
with many ribosomal protein subunits as determined by mass spectrometry 
based proteomics.  Finally, Gis2p is able to activate cap-independent translation 
of the ODC IRES in human tissue culture cells.  These data together suggest that 
the S. cerevisiae protein Gis2p and the mammalian protein ZNF9 are functional 
orthologs and provide a novel system to study the molecular function of ZNF9 in 
translation and other essential cellular processes.  
 
Materials and methods 
 
Yeast strains and plasmids 
Yeast genetic manipulations and media preparation were performed 
essentially as described.  The gis2 deletion strain used in this study had the 
entire gis2 ORF replaced by a kanamycin cassette in the BY4743 background 
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(MATa/α his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 lys2Δ0/LYS2 MET15/met15Δ0 
ura3Δ0/ura3Δ0) (Winzeler, Shoemaker et al. 1999). Knockout strains of gis2 
were confirmed by PCR-based amplification across the kanR locus and growth of 
the strains on G418-containing medium.  Yeast strains with the Gis2p tandem-
affinity-purification tags have been described (Ghaemmaghami, Huh et al. 2003).   
 
Tandem Affinity Purification 
Gis2p was purified from 1 L cultures of a Gis2p-TAP-tagged yeast strain 
(Ghaemmaghami, Huh et al. 2003) grown to early stationary phase (O.D.600 2-4).  
Gis2p and associated proteins were isolated using a dual affinity protocol as 
previously described (Link, Fleischer et al. 2005).  10% of the eluted proteins 
were analyzed by SDS-PAGE on 4-12% Novex Bis-TRIS gels (Invitrogen) and 
silver stained.  The remaining eluted proteins were reduced with DTT, alkylated 
with iodoacetamide, and digested with sequencing grade trypsin (Promega) for 
LC-MS/MS analysis.   
 
Western Blotting 
Anti-TAP serum (OPEN Biosystems) was used at a 1:1000 dilution.  Anti-
HA-HRP (Pierce) was used at 1:10,000.  All primary antibodies were diluted in 
5% non-fat dry milk and TBST (TRIS-buffered saline and 0.1% TWEEN-20) 
supplemented with 0.04% NaN3.   
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Mass Spectrometry-based Proteomics and Data Analysis 
Trypsin-digested peptides were identified using two dimensional 
microcapillary liquid chromatography coupled with an LTQ linear ion trap mass 
spectrometer (Thermo Electron, Inc) as described previously (Link, Eng et al. 
1999; Link, Fleischer et al. 2005).  Acquired mass spectra were correlated to a 
translated Saccharomyces cerevisiae ORF database using Sequest  (Eng, 
McCormack et al. 1994).  The resulting peptide hits were analyzed, clustered, 
and visualized using BIGCAT ((McAfee, Duncan et al. 2006).  
  
Polysome Profiling 
For the isolation of ribosomes by sucrose gradient centrifugation, Gis2-
TAP-tagged strains were grown in 10 mL of SC-HIS to an O.D.600 of 0.8.  
Cycloheximide was added to a concentration of 50 μg/mL, and the cultures were 
placed on ice for 10 min.  Cells were pelleted, washed with cold phosphate 
buffered saline, and lysed with 0.5 mm glass beads in 500 μL of lysis buffer (10 
mM Tris-HCl, pH 8.0, 140 mM NaCl, 1.5 mM MgCl2, 0.5% NP40, 10 mM DTT, 
300 μg/mL heparin, 100 μg/mL cycloheximide and 250 U/mL RNASIN 
(Promega).  Cellular debris was cleared by centrifugation at 20,000 x g for 10 
min.  Supernatants (100μl) were layered on top of 10-40% sucrose gradients in 
10 mM Tris-HCl, pH 7.5, 140 mM NaCl, 1.5 mM MgCl2, 10 mM DTT, 100 μg/mL 
cyclohexamide, and 0.5 mg/ml heparin. Gradients were centrifuged in a 
Beckman SW-41 swinging bucket rotor for 60 min at 38,000 rpm. 1 mL fractions 
were collected by bottom displacement with on-line UV280 measurements 
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(Agilent).  Fractions were TCA-precipitated and 50% of the total protein was 
analyzed by SDS-PAGE and western blotting using anti-TAP serum (OPEN 
Biosystems) at 1:1000. 
 
Ribosome pelleting and ribosome salt wash experiments 
 
Ribosome pelleting experiments were performed by centrifugation of 
whole cell lysates described above through a 1 M sucrose cushion (-/+ 10mg/mL 
RNAse H or 50mM EDTA) at 100,000xg for 2 h in a TLA120.2 rotor.  The 
resulting ribosome pellet was resuspended in ribosome solubilization buffer (20 
mM TRIS pH 7.5, 5 mM MgCl2, 6 M urea).  Supernatant fractions were 
precipitated with trichloroacetic acid, washed with acetone, and resuspended in 
ribosome solubilization buffer.  For ribosome salt wash analysis, ribosome pellets 
were isolated as described above, and the intial supernatants were discarded.  
Pellets were washed in ice cold PBS and resuspended in ribosome salt wash 
buffer containing 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM BME, and either 
100 mM, 250 mM, 500 mM, or 1 M potassium acetate.  Resuspended ribosomes 
were then centrifuged at 100,000xg for 2 h in a TLA120.2 rotor.  Supernatant 
fractions were removed and TCA precipitated as described above, and pellet 
fractions were resuspended in solubilization buffer.  Equal volumes of lysate 
were separated by polyacrylamide gel electrophoresis, transferred to 
nitrocellulose membranes, and immunoblotted using α-TAP antibodies.   
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Growth defect and translation inhibitor selection assays 
Yeast strains were grown in either SC or SC+G418 (0.2mg/ml) to an 
O.D.600 of 0.6. Cells were counted with a hemocytometer, adjusted to equal 
concentration, and serially diluted (10 fold). Five μL of each 10-fold serial dilution 
was spotted onto the appropriate test plates.  Growth assays to test salt 
sensitivity were performed with either 0.5M or 1M NaCl.  Translation inhibitors 
were added to the media at the following concentrations: hygromycin (100 
μg/mL), paromomycin (0.4 mg/mL), anisomycin (100 μg/mL), rapamycin (25 
ng/mL), and cycloheximide (0.2 μg/mL and 2 μg/mL). For growth on galactose, 
standard YPD media was prepared replacing 20g/L dextrose with 20g/L of 
galactose. For heat shock experiments, log-phase yeast cells were incubated in 
prewarmed (45°C) YPD for 15 minutes, and then plated on YPD plates as 
described above. The plates were incubated for 48 hours and then 
photographed.   
 
Tissue culture assay for cap-independent translation 
HEK293T cells were cultured in 10 cm tissue culture-treated plates using 
DMEM and 10% fetal bovine serum at 37°C and 5% CO2.  pcDNA3.1-hODC-
IRES, pcDNA3.1-V5-LacZ, and pcDNA3.1-V5-ZNF9 were previously described 
(Sammons, Antons et al. 2010).  pcDNA3.1-V5-Gis2 was created by Gateway-
mediated recombination of pcDNA3.1-V5-ccdB (Invitrogen) and pENTR-Gis2, 
which was created by cloning the gis2 coding sequence amplified from yeast 
genomic DNA using the sense primer  5’- CACCAT 
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GTCTCAAAAAGCTTGTTACG-3’ and the antisense primer 5’-
CTAAGCCTTTGGACAATCCT-3’.  Equal amounts of pcDNA3.1-hODC-IRES and 
a plasmid expressing either ZNF9, Gis2p, or β-galactosidaese were transfected 
into HEK293T cells using Lipofectamine (Invitrogen) following themanufacturer’s 
recommendations.  After 24 hours, cells were collected and processed for 
luciferase assays according to the manufacturer’s recommendations (Promega, 
Dual Luciferase Assay Kit).  Cap-independent translation activity is reported as 
previously described (Sammons, Antons et al. 2010).   
 
Cloning of Znf9 deletion mutants 
 To create deletion mutants of ZNF9, PCR amplified products using the 
following primers on full-length pcDNA3.1-V5-ZNF9 were cloned into pENTR-
D/TOPO (Invitrogen).  For the Δ7, Δ6, and Δ5 mutants, the sense primer was 
 5’ CACCATGAGCAGCAATGAGTGCTT-3’. 
Antisense Δ7: 5’- TTATTCACTTGTCTTGCTGCAGT-3’.  
Antisense Δ6: 5’-TTATTTGGTGCAGTCTTTTTGAA-3’.  
Antisense Δ5: 5’-TTACTCATCTGCATGGTCGCAGT-3’.  The antisense primer 
for the Δ1 and ΔRGG mutants was 5’-AGGCTGTAGCCTCAATTGTGCATTC-3’.   
Sense primer for Δ1: 5’-CACCATGACTGGTGGAGGCCGTGGTCG-3’.  Sense 
primer for ΔRGG: 5’-CACCATGATTTGTTATCGCTGTGGTGA-3’.  Destination 
clones were created by Gateway-mediated recombination of individual entry 
clones with pcDNA3.1-V5-ccdB (Invitrogen).  All plasmids were sequence verified 
by the Vanderbilt DNA Sequencing Facility.  Fusion with the V5-tag was verified 
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by western blotting analysis using α-V5 monoclonal antibody (Invitrogen).  The 
ability of the ZNF9 mutants to activate cap-independent translation was assessed 
as described above.   
 
 
Results 
 
ZNF9 is evolutionarily conserved in eukaryotes 
Previous studies have implicated ZNF9 in a wide variety of molecular 
functions, ranging from the regulation of transcription to the control of cell growth 
and proliferation (Pellizzoni, Lotti et al. 1997; Chen, Liang et al. 2003; Abe, Chen 
et al. 2006; Weiner, Allende et al. 2007; Armas, Aguero et al. 2008).  Because 
ZNF9 is absolutely required for the viability of vertebrate organisms (Chen, Liang 
et al. 2003; Shimizu, Chen et al. 2003), genetic analysis of ZNF9 function is 
impossible in these complex animals.   The exact roles or molecular functions of 
ZNF9 are unknown, partially due to a lack of a simple model organism in which to 
study ZNF9 biochemical and genetic activity.  Using the NCBI tool Homologene, 
which searches for homologous proteins throughout all fully sequenced and 
annotated eukaryotic genomes, we found putative ZNF9 orthologs in multiple 
organisms (Figure 5)  Interestingly, the Saccharomyces cerevisiae protein Gis2p 
has high levels of homology to ZNF9 in both sequence and in domain 
architecture (Figure 6).  ZNF9 and its vertebrate homologs contain seven CCHC-
type zinc fingers, with an RGG box between the first and second zinc finger 
(Figures 5 and 6).  ZNF9 homologs seem to cluster into specific groups, 
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vertebrate, cartilaginous fish, insects, and fungi.  While the putative fungi 
homologs, including Gis2p have seven CCHC-type zinc finger domains, neither 
Gis2p nor the S. pombe homolog contains an RGG box.     
While Gis2p contains significant sequence similarity with the Homo 
sapiens ZNF9 protein, it is unknown whether the two proteins can be considered 
functional orthologs.  In order to demonstrate orthology, we determined whether 
Gis2p has biochemical properties and interactions similar to ZNF9.  Previously, 
ZNF9 was found to associate with the translating ribosome and act as a regulator 
of cap-independent translation (Sammons, Antons et al. 2010).   
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10 20 30 40 50 60
. . . . |. . . . | .. . . | . . .. | . . . .| . . . . | .. . . | . .. . | . . .. | . . . . |. . . . | .. . . |
[Homo sapiens] M-SSN------------ECFKCGRSGHWARECP------------TGGGRGRGMRSRGR-
[Bos taurus] M-SSN------------ECFKCGRSGHWARECP------------TGGGRGRGMRSRGR-
[Canis familiaris] M-SSN------------ECFKCGRSGHWARECP------------TGGGRGRGMRSRGRG
[Rattus norvegicus] M-SSN------------ECFKCGRSGHWARECP------------TGGGRGRGMRSRGRG
[Mus musculus] M-SSN------------ECFKCGRSGHWARECP------------TGGGRGRGMRSRGRG
[Gallus gallus] M-SSN------------ECFKCGRTGHWARECP------------TGIGRGRGMRSRGRA
[Danio rerio] M-STS------------ECFGCGRSGHWIKNCP------------NA-GRGRG-RGRGRG
[Drosophila melanogaster] MSMSA------------TCYKCNRPGHFARDCSLGGGGGPGGVGGGGGGGGGGMRGNDGG
[Anopheles gambiae] MMSTN------------TCFKCDRPGHYARDCQ--------NVGGGGGRGVGGPRDRRDF
[Saccharomyces cerevisiae] M-SQK------------ACYVCGKIGHLAEDCD---------------------------
[Schizosaccharomyces pombe] MESESVPTVPQTTRPGPRCYNCGENGHQARECT---------------------------
70 80 90 100 110 120
. . . . |. . . . | .. . . | . . .. | . . . .| . . . . | .. . . | . .. . | . . .. | . . . . |. . . . | .. . . |
[Homo sapiens] ------GFQFVSSSLPDICYRCGESGHLAKDCDL----QEDVEACYNCGRGGHIAKDCK-
[Bos taurus] ------GFQFVSSSLPDICYRCGESGHLAKDCDL----QED--ACYNCGRGGHIAKDCK-
[Canis familiaris] GFTSDRGFQFVSSSLPDICYRCGESGHLAKDCDL----QED--ACYNCGRGGHIAKDCK-
[Rattus norvegicus] GFTSDRGFQFVSSSLPDICYRCGESGHLAKDCDL----QED--ACYNCGRGGHIAKDCK-
[Mus musculus] GFTSDRGFQFVSSSLPDICYRCGESGHLAKDCDL----QED-EACYNCGRGGHIAKDCK-
[Gallus gallus] ------GFQFMSSSLPDICYRCGESGHLAKDCDL----QED-KACYNCGRGGHIAKDCK-
[Danio rerio] --------------KDLFCYRCGEQGHIARDCEQ----TED--ACYNCHRSGHISRDCK-
[Drosophila melanogaster] GMRR----------NREKCYKCNQFGHFARACPE----EAE--RCYRCNGIGHISKDCT-
[Anopheles gambiae] G-------------RREKCYKCNQMGHFARDCKE----DLD--RCYRCNGSGHIARDCSL
[Saccharomyces cerevisiae] --------------SERLCYNCNKPGHVQTDCTMPRTVEFK--QCYNCGETGHVRSECTV
[Schizosaccharomyces pombe] --------------KGSICYNCNQTGHKASECTEPQ--QEK--TCYACGTAGHLVRDCPS
130 140 150 160 170 180
. . . . |. . . . | .. . . | . . .. | . . . .| . . . . | .. . . | . .. . | . . .. | . . . . |. . . . | .. . . |
[Homo sapiens] EPKREREQCCYNCGKPGHLARDCDHADEQKCYSCGEFGHIQKDCTKVKCYRCGETGHVAI
[Bos taurus] EPKREREQCCYNCGKPGHLARDCDHADEQKCYSCGEFGHIQKDCTKVKCYRCGETGHVAI
[Canis familiaris] EPKREREQCCYNCGKPGHLARDCDHADEQKCYSCGEFGHIQKDCTKVKCYRCGETGHVAI
[Rattus norvegicus] EPKREREQCCYNCGKPGHLARDCDHADEQKCYSCGEFGHIQKDCTKVKCYRCGETGHVAI
[Mus musculus] EPKREREQCCYNCGKPGHLARDCDHADEQKCYSCGEFGHIQKDCTKVKCYRCGETGHVAI
[Gallus gallus] EPKREREQCCYNCGKPGHLARDCDHADEQKCYSCGEFGHIQKDCTKVKCYRCGETGHVAI
[Danio rerio] EPKKEREQCCYNCGKAGHVARDCDHANEQKCYSCGGFGHIQKLCDKVKCYRCGEIGHVAV
[Drosophila melanogaster] QAD---NPTCYRCNKTGHWVRNCPEAVNERG------------PTNVSCYKCNRTGHISK
[Anopheles gambiae] SPD---DSCCYNCNQSGHLARNCPEKSDR--------------DMNVSCYNCNKSGHISR
[Saccharomyces cerevisiae] Q-------RCFNCNQTGHISRECPEPKKTSR------------FSKVSCYKCGGPNHMAK
[Schizosaccharomyces pombe] SPNPRQGAECYKCGRVGHIARDCRTNGQQSG------GRFGGHRSNMNCYACGSYGHQAR
190 200 210 220 230
. . . . |. . . . | .. . . | . . .. | . . . .| . . . . | .. . . | . .. . | . . .. | . . . . |. . . . |
[Homo sapiens] NCSK---TSEVNCYRCGESGHLARECTIEA-----------------------TA
[Bos taurus] NCSK---TSEVNCYRCGESGHLARECTIEA-----------------------TA
[Canis familiaris] NCSK---TSEVNCYRCGESGHLARECTIEA-----------------------TA
[Rattus norvegicus] NCSK---TSEVNCYRCGESGHLARECTIEA-----------------------TA
[Mus musculus] NCSK---TSEVNCYRCGESGHLARECTIEA-----------------------TA
[Gallus gallus] NCSK---TSEVNCYRCGESGHLARECTIEA-----------------------TA
[Danio rerio] QCSK---ATEVNCYNCGKTGHLARDCSIEA-----------------------SA
[Drosophila melanogaster] NCPE----TSKTCYGCGKSGHLRRECDEKGG----------------------RN
[Anopheles gambiae] NCPS----GDKSCYSCGKIGHLSRDCTENKG----------------------RD
[Saccharomyces cerevisiae] DCMKEDGISGLKCYTCGQAGHMSRDCQNDR---LCYNCNETGHISKDCP----KA
[Schizosaccharomyces pombe] DC-----TMGVKCYSCGKIGHRSFECQQASDGQLCYKCNQPGHIAVNCTSPVIEA
Figure 5. Multiple sequence alignment of putative ZNF9 homologs. 
Using the National Center for Biotechnology Information’s Homologene 
software, putative homologs to the human ZNF9 protein were identified.  
Amino acid sequences of all putative homologs were aligned using MAFFT 
(Multiple Alignment by Fast Fourier Transform (Katoh, Misawa et al. 2002)).  
Boxed regions represent aligned CCHC-type zinc finger motifs.   
Figure 5 
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Figure 6 
 
 
 
 
Figure 6. Phylogenetic analysis and functional domain analysis reveal 
a Saccharomyces cerevisiae homolog to the human ZNF9 protein. 
A. Phylogenetic analysis (Katoh, Misawa et al. 2002) groups the putative 
homologs of ZNF9 (Figure 3-1)  based upon their divergence from the 
human ZNF9 amino acid sequence.  Vertebrate ZNF9 homologs are all 
identical to the human protein, while cartilaginous fish, insects, and fungi 
are in their own distinct groups.  B.  ZNF9 and the Gis2 share very similar 
domain architectures and sequences, suggesting that they may be 
functional orthologs.   
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Saccharomyces cerevisiae Gis2p copurifies with the eukaryotic ribosome 
To examine whether Gis2p and ZNF9 have conserved interactions with 
other proteins, we used tandem affinity purification (TAP) followed by tandem 
mass spectrometry to identify proteins that associate with Gis2p.  This approach 
has been extensively used to identify and characterize protein:protein 
interactions in yeast  (Gavin, Bosche et al. 2002; Gavin and Superti-Furga 2003; 
Gavin, Aloy et al. 2006).  Following TAP-isolation, the eluted proteins were 
separated by SDS-PAGE and visualized by silver staining, as seen in Figure 7.  
Affinity purification of Gis2p yielded a large set of co-purifiy proteins, the majority 
of which were below 40kDa.  We identified the co-purifying proteins by shotgun 
LC-MS/MS analysis as previously described (Link, Eng et al. 1999; Link, 
Fleischer et al. 2005; Fleischer, Weaver et al. 2006).  The mass spectrometry 
data were processed and analyzed using the BIGCAT software suite (McAfee, 
Duncan et al. 2006).  Semi-quantitative protein abundance factors (PAF) were 
computed for each identified protein to give a relative measure of the abundance 
of each protein (McAfee, Duncan et al. 2006).  Based on this quantification 
method, the most abundant co-purifying proteins were ribosomal subunits and 
other translation related proteins (Figure 7 and Appendix A, Table A1).  
Hierarchal clustering of data from three replicate experiments revealed that 
Gis2p reproducibly copurifies with ribosomes and other translation factors, but 
also copurifies with other proteins not found in ribosome isolations (Figure 7 and 
Appendix A, Table A1).    Similarly, immunoprecipitation of ZNF9 from HeLa cells 
followed by shotgun proteomic analysis revealed interactions with the human 
 68
ribosome machinery (Appendix A, Table A2).  These data suggest that Gis2p 
copurifies with components of the eukaryotic ribosome and provide evidence of 
biochemical interactions are conserved between Gis2p and ZNF9.   
 69
FIGURE 7 
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Figure 7. Purification of Gis2-TAP reveals the interactome of Gis2p.  
A.Eluted proteins from TAP protocol from a Gis2-TAP expressing strain and 
an untagged parental strain.  10% of eluted proteins were analyzed by SDS-
PAGE and silver stained.  MWM-molecular weight markers. B. Heirarchal 
clustering of 3 replicate Gis2-TAP purifications compared to 4 replicate 
isolations of ribosomes from mass spectrometry data.  On the heat map, protein 
abundance is measured from black representing no protein identified to bright 
red meaning high abundance.  Notice the significant overlap in the proteins 
copurified with Gis2-TAP and purified ribosomes.   
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Polysome analysis reveals Gis2p colocalizes with the ribosome 
 To test whether copurification of Gis2p with ribosomal subunits and the 
translation machinery is a result of in vivo association with the ribosome during 
translation, we isolated ribosomes by differential centrifugation and assayed the 
presence of Gis2p.  Initially, lysates from a Gis2p-TAP-tagged strain were loaded 
onto a sucrose cushion and subjected to ultracentrifugation to isolate 
polyribosomes.  As seen in Figure 8B, the large majority of Gis2p is found in the 
polysome pellet, which suggests that Gis2p associates with the translating 
ribosome.  We confirmed this result in linear sucrose gradient ultracentrifugation 
experiments.  As seen in Figure 8A, Gis2p is found in the heavy polysome-
containing fractions.  In both centrifugation strategies, a small population of 
Gis2p was found in the non-ribosomal fractions, suggesting that not all of the 
cellular Gis2p is actively associated with the ribosome.  Human ZNF9 shows the 
same pattern of localization: predominantly ribosomal, with a small non-ribosome 
pool (Sammons, Antons et al. 2010).   
Ribosome salt wash experiments have been used to separate core 
ribosomal subunits from associated translation factors, and were used to 
determine the relative strength of human ZNF9’s ribosome interaction 
(Sammons, Antons et al. 2010).  We reasoned that Gis2p and ZNF9 should elute 
from the ribosome at similar salt concentrations if they are biochemical and 
functional orthologs.  As seen previously for human ZNF9, Gis2p is absent from 
the wash fractions at low salt concentrations (100mM and 250mM potassium 
acetate) (Figure 8C).  At the 500mM salt concentration, Gis2p begins to elute 
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from the ribosome pellet, and at 1M salt, all of the Gis2p is found in the wash 
fraction.  These results are similar to what was previously observed with human 
ZNF9 and suggest that the Gis2p interaction with the ribosome is similar to that 
of other translation factors but not quite at the strength of core ribosomal subunits 
(Sammons, Antons et al. 2010).  The similar ribosomal interactions of Gis2p and 
ZNF9 provide evidence that they are putative biochemical orthologs and suggest 
that they function in the essential cellular process of translation.    
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FIGURE 8 
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Figure 8. S. cerevisiae Gis2p interacts with the ribosome. 
A. Polysome analysis of sucrose gradient ultracentrifugation fractions for 
Gis2p were measured by bottom displacement and on-line UV260 
measurements.  10% of each fraction was analyzed by western blotting 
for the presence of Gis2.  B. Western blot analysis for the presence of 
Gis2p in whole cell lysates (WCL), supernatant (SUP), or pellet (PEL) 
fractions after isolation of polysomes from Gis2-TAP-tagged cells. C. 
Ribosome salt wash and western analysis for Gis2p.  Potassium acetate 
was used as the salt in salt wash buffers.   
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Gis2p-Ribosome interactions are sensitive to RNAse 
The data shown in Figure 8 strongly suggests that Gis2p interacts with the 
translating ribosome, but the data do no suggest a mechanism behind the 
interaction.  Because of the polysomal localization of Gis2p, we tested whether 
Gis2p’s ribosome association required tethering through mRNA by treatment with 
either RNAse A.  RNAse A specifically cleaves single-stranded RNA.  Lysates of 
Gis2-TAP expressing cells were mock-treated or treated with 50μg/mL of RNAse 
A for 30 minutes at room temperature and then Gis2-TAP was purified and 
subjected to western blot analysis and mass spectrometry based proteomics.  
Interestingly, even though more Gis2p was purified in RNAse-treated samples, 
less ribosomal proteins were identified by mass spectrometry.  This result 
suggests that RNAse A-treatment releases Gis2-TAP from the ribosome and 
makes the purification scheme more efficient.  To confirm that RNAse A- 
treatment releases Gis2p from ribosomes, ribosomes were pelleted and then 
resuspended in ribosome wash buffer supplemented with either RNAse A or 
EDTA.  EDTA disrupts polyribosomes and has been shown to disrupt the 
interaction between certain RNA binding proteins and the ribosome, including 
human ZNF9 (Sammons, Antons et al. 2010). Ribosomes were then reisolated 
through a sucrose cushion and analyzed for the presence of Gis2p.  As seen in 
Figure 9B, treatment of ribosomes with RNAse or EDTA results in a large 
decrease in Gis2p association, suggesting that Gis2p interacts with actively 
translating ribosomes and that this interaction requires an interaction with either 
mRNA or RNAse-sensitive rRNA.   
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FIGURE 9 
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Figure 9. Gis2p interacts with the translating ribosome through associations 
with single-stranded RNA. A. Protein abundance factors of a subset of proteins 
isolated by purification of Gis2-TAP in the presence or absence of RNAse. Also, 
western blot analysis of eluted proteins shows the abundance of isolated Gis2-TAP 
in the presence or absence of RNAse.  B. Western blot analysis  for Gis2-TAP of 
solubilized polysome pellets in the presence of EDTA or RNAse.   
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Knockout of Gis2p function results in no obvious growth phenotype  
 In an effort to identify the function of Gis2p, we analyzed the phenotypes 
of a gis2 mutant.   An S. cerevisiae gis2 knockout mutant was created previously 
and no obvious growth defect or lethality was observed (Winzeler, Shoemaker et 
al. 1999).  Because of Gis2p’s proposed role in translation, we reasoned that this 
mutant would be sensitive to conditions that perturb normal cellular translation.  
Using traditional spot dilution growth assays, we tested growth of a homozygous 
diploid gis2 null mutant and its parental strain under many conditions known to 
disturb translation, such as high temperature, high osmolarity, a poor carbon 
source, heat shock.  We also tested several chemicals that specifically inhibit 
translation.  Deletion of gis2 does not cause any discernible growth defect when 
compared to the parental strain under any of the tested conditions (Figure 10).    
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Figure 10 
 
 
 
Figure 10. Spot dilution growth assays of gis2 mutants. 
Growth assays of either wild-type parental strains (top of panel) or gis2 knock-out 
strains (bottom of panel) under a variety of conditions that perturb translation.  
Conditions are described in the Materials and Methods section.  
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Expression of Gis2p activates cap-independent translation of the ODC 
IRES in HEK293T cells  
 
In analyzing whether Gis2p is an ortholog of ZNF9, one of our critical 
considerations was function.  We wanted to test whether Gis2p and ZNF9 can 
functionally substitute for each other.  Because we did not identify any 
phenotypes resulting from loss of Gis2p, we were unable to do this experiment in 
yeast.  Instead, we used human tissue culture cells.  Previously, we showed that 
ZNF9 functions as an activator of cap-independent translation in mammalian 
cells.  We reasoned that if Gis2p were a true ortholog of ZNF9, it might also be 
able to facilitate activation of IRES targets, namely the ODC IRES.  To measure 
cap independent translation, we used a previously characterized bicistronic 
reporter plasmid system (Sammons, Antons et al. 2010).  The ODC-IRES 
reporter encodes the Renilla luciferase gene upstream of the firefly luciferase 
gene.  The full-length 5’UTR of the ODC gene is fused between the two open 
reading frames.  The full-length coding sequence of Gis2p, ZNF9, and an 
unrelated protein (β-galactosidase) were placed downstream of a V5 epitope tag 
in a mammalian expression plasmid.  Co-expression of the ODC-IRES reporter 
with V5-ZNF9 in HEK293T cells activated translation of the ODC IRES, whereas 
co-expression with V5-β-Gal did not.  Interestingly, expression of V5-Gis2p 
activated cap-independent translation of the reporter at levels similar to V5-ZNF9 
(Figure 11).  These results show that Gis2p is an activator of IRES-dependent 
ODC translation and provide further evidence that Gis2p and ZNF9 are functional 
and biochemical orthologs.   
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Figure 11 
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Figure 11. Expression of Gis2p in HEK293T cells activates IRES-
dependent translation.  A. Schematic representation of the bicistronic 
ODC-IRES reporter.  B.  HEK293T cells expressing the bicistronic reporter 
and either LacZ, ZNF9, or Gis2p were analyzed for luciferase activity.  
Cap-independent translation is reported as a ratio of Cap-independent 
translation (reporter #2, firefly luciferase) to cap-dependent translation 
(reporter #1, Renilla luciferase).  Data represents 3 independent 
experiments, and error bars represent the standard deviation.   
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A conserved C-terminal region of ZNF9 is required for full cap-independent 
translation activation 
 
 We reasoned that the region of Gis2p responsible for cap-independent 
translation activity is found in the evolutionarily conserved regions or domains 
shared with ZNF9.   Gis2p contains 7 sequential CCHC-type zinc finger motifs 
and no other conserved functional domains.  ZNF9 additionally contains an RGG 
box motif between the first and second zinc fingers.  To test the regions of ZNF9 
that are required for cap-independent translation activity, we created a series of 
N and C-terminal deletion mutants, as shown in Figure 12.  Each of these 
mutants was co-expressed with the ODC IRES reporter and cap-independent 
translation activity was measured.   Deletion of either the first CCHC-zinc finger 
or the first zinc finger in combination with the RGG box had no effect on the 
ability of ZNF9 to activate cap-independent translation.  The Δ5 mutant, lacking 
the fifth, sixth, and seventh zinc fingers, fails to fully activate cap-independent 
translation, whereas the Δ6 mutant, lacking only the sixth and seventh zinc 
fingers, shows no difference in activity compared to the wild-type ZNF9.  These 
data demonstrate that the RGG box of ZNF9, which is not found in Gis2p, is not 
important for cap-independent translation activity, but that an intact fifth CCHC-
zinc finger is necessary for full activation of translation.  Collectively, the data 
presented here show that Gis2p is a functional ortholog of the mammalian ZNF9 
protein and suggest that information gleaned from the study of Gis2p in yeast is 
relevant to the understanding of ZNF9.   
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FIGURE 12 
 
 
 
Figure 12. A conserved C-terminal region of ZNF9 is required for full cap-
independent translation activity.  A. Schematic representation of the various 
ZNF9 mutants. B. HEK293T cells were transfected with the ODC-IRES 
reporter and the indicated plasmids and cap-independent translation activity 
was measured.  Cap-independent translation activity is depicted as a ratio of 
cap-independent translation to cap-dependent translation.  Data represents 3 
independent experiments.  Error bars represent the standard deviation.    C. 
Western blot analysis of V5-tagged ZNF9 mutant and Gis2p protein 
expression in HEK293T cells.   
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Discussion 
 
Gis2p has evolutionarily conserved functions in translation 
Because proteins are the critical catalysts of all cellular functions, 
eukaryotic cells have sophisticated and diverse mechanisms to temporally and 
spatially control protein synthesis.  This work provides evidence that the 
Saccharomyces cerevisiae protein Gis2p is part of an evolutionarily conserved 
mechanism to control translation of specific mRNA molecules that contain 
internal ribosome entry sites.  IRES-driven translation is theorized to have 
developed in viruses as a mechanism to allow for translation of viral mRNAs after 
the shutdown of the canonical cap-dependent translation pathway.  Multiple 
studies have demonstrated cap-independent translation in S. cerevisiae, of both 
viral and endogenous cellular mRNA molecules (Thompson, Gulyas et al. 2001; 
Komar, Lesnik et al. 2003; Komar and Hatzoglou 2005; Gilbert, Zhou et al. 2007).  
IRES-mediated translation of viral mRNAs is thought to occur through conserved 
secondary structure inherent to the IRES itself, but IRES-mediated  translation of 
cellular RNAs is believed to require sequence specific cofactors, or ITAFs.  The 
Doudna laboratory demonstrated that cap-independent translation of certain 
mRNAs is required for haploid invasive growth, the first demonstrated 
physiological role for cap-independent translation in yeast (Gilbert, Zhou et al. 
2007). Since Gis2p functions in cap-independent translation in human cells, it 
would be interesting to test whether gis2 mutants are defective in invasive 
growth. It remains to be seen whether Gis2p functions as an ITAF for any of the 
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known yeast IRES-containing mRNAs, but the conserved function of Gis2p in 
mammalian IRES-mediated translation suggests that Gis2p likely acts as an 
ITAF in yeast.  No mRNA-specific ITAFs have been identified yet in yeast 
(Thompson, Gulyas et al. 2001; Komar, Lesnik et al. 2003; Komar 2005; Landry, 
Hertz et al. 2009).  Further investigation into what, if any, yeast cellular IRESs 
are regulated by ITAFs, and Gis2p in particular, will be needed to fully 
understand the physiological role of cap-independent translation in yeast and 
other eukaryotic organisms.   
 
Gis2p and ZNF9 share common biochemical interactions 
As demonstrated here and previously (Sammons, Antons et al. 2010), 
Gis2p and ZNF9 associate with the eukaryotic ribosome and act as regulators of 
cap-independent translation.  ZNF9 interacts with other known ITAFs, such as 
PCBP2 and the La protein (Pellizzoni, Lotti et al. 1998; Cardinali, Carissimi et al. 
2003; Schlatter and Fussenegger 2003; Gerbasi and Link 2007) that may have 
vital roles in regulating the cap-independent translation activity of ZNF9.  
Interestingly, the S. cerevisiae protein Sro9p is a putative ortholog of the 
mammalian La protein and was identified as a potential Gis2p interactor in our 
studies (Table 3-1).  The Michnick group recently showed a putative interaction 
between Sro9p and Gis2p by genome-wide protein-fragment complementation 
assay (Tarassov, Messier et al. 2008).  Sro9p was initially identified as a 
multicopy suppressor of an RNA export defect and was shown to associate with 
polysomes (Kagami, Toh-e et al. 1997; Sobel and Wolin 1999).  Recently, Sro9p 
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was shown to associate with nascent transcripts and form part of an mRNP 
complex that is exported to the cytoplasm, where Sro9p then acts as a regulator 
of translation (Rother, Burkert et al. 2010).  Our current hypothesis is that Gis2p 
and Sro9p directly interact, similar to ZNF9 and La, and that a protein complex 
containing these proteins work together to stimulate translation in yeast.  The 
yeast model system offers intriguing opportunities to study Gis2p and Sro9p and 
their potentially conserved cellular roles in translation.   
   
Using S. cerevisiae as a model system to study ZNF9 function and the 
regulation of cap-independent translation 
 
The eukaryotic translation machinery is extremely well-conserved from 
yeast to man.  The rapid growth rate and the ease of identifying mutants make 
yeast a very tractable model system in which to study the essential cellular 
process of protein synthesis.  Many important discoveries, including the identities 
and activities of various translation factors and the identities of all of the 
components of the eukaryotic ribosome, were first made in S. cerevisiae.  While 
the role that ZNF9 plays in the progression of myotonic dystrophy type 2 is best 
studied in the context of mammalian cells, the role of ZNF9 in cap-independent 
translation can be addressed using a variety of approaches yeast to identify 
novel regulators and functions of the ZNF9 homolog, Gis2p. As previously 
discussed, the conservation of ITAF activity between ZNF9 and Gis2p suggests 
that the molecular and biochemical interactions and activities of Gis2p in yeast 
are directly relevant to our understanding of ZNF9 function.  Recently developed 
genetic tools, such as E-MAP (Collins, Schuldiner et al. 2006; Fiedler, Braberg et 
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al. 2009), should allow for the further identification of potential Gis2p biochemical 
interactors and genetic pathways in which Gis2p is involved.  
 Although previous work suggested that ZNF9 plays a role in cell proliferation, 
gis2 mutants grew at a similar rate under all conditions tested, suggesting that 
any role of ZNF9 in cell proliferation is not shared by Gis2p.  One interesting 
possibility is that the RGG box of ZNF9, which is not found in Gis2p, functions in 
the control of cell proliferation and growth.  Further studies are needed to 
understand what role the different conserved and unique functional domains play 
in the multiple roles of ZNF9 and Gis2p.   
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CHAPTER IV 
 
PROTEOMIC ANALYSIS OF SKELETAL MUSCLE FROM MYOTONIC 
DYSTROPHY TYPE 2 MURINE MODELS 
 
 
Abstract 
Myotonic dystrophy type 2 is caused by a tetranucleotide expansion in the 
first intron of the znf9 gene.  The prevailing disease mechanism suggests that 
transcribed repeat RNA causes cellular toxicity, leading to pathological 
symptoms.  Despite the prevalence of the RNA toxicity model, alternative models 
for the mechanism of DM2 have not been ruled out or tested.  In this chapter, I 
test the model that ZNF9 activity is reduced in DM2 and contributes to DM2 
disease progression by examining changes in protein expression in murine 
models of myotonic dystrophy using quantitative mass spectrometry-based 
proteomics.   
 
Introduction 
 
A nucleotide expansion in the znf9 gene causes the human disease 
myotonic dystrophy type 2 
 
Nucleotide repeat expansion (NRE) disorders define a large class of 
human pathologies that share the common characteristic of large, mutated tracts 
of repeat DNA that confer either a loss or gain of function phenotype.  The 
human disease myotonic dystrophy type 2 (DM2) is caused by an expansion of 
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the CCTG tetranucleotide repeat in the first intron of the ZNF9 gene (Liquori, 
Ricker et al. 2001).  A similar disorder, myotonic dystrophy type 1 (DM1), results 
from the expansion of a CTG trinucleotide repeat in the 3’UTR of the DMPK gene 
(Brook, Mccurrach et al. 1992).  The nucleotide expansion occurs in untranslated 
regions of the ZNF9 transcripts, leading to the production of seemingly normal 
protein products (Margolis, Schoser et al. 2006).  Expression of the expanded 
repeats in unrelated genes causes myotonic dystrophy like symptoms, 
suggesting that the mere presence of the expansion, rather than the context of 
the mutation, gives rise to the myotonic dystrophies (Mankodi, Logigian et al. 
2000; Amack and Mahadevan 2001; Seznec, Agbulut et al. 2001).  These 
observations collectively have led to the development of the RNA toxicity model 
for myotonic dystrophy.  The hypothesis suggests that the transcribed, but 
untranslated nucleotide repeat expansions form stable RNA structures that are 
toxic to the cell.  The toxicity is believed to stem from the ability of specific 
cellular proteins, such as MBNL and CUGBP1, to bind to the aberrant RNA 
structures (Fardaei, Larkin et al. 2001; Kanadia, Johnstone et al. 2003; de Haro, 
Al-Ramahi et al. 2006; Hino, Kondo et al. 2007).  Interaction with the stable RNA 
substrates is thought to either inactivate certain proteins, such as the RNA 
splicing factor MBNL, or confer greater activity upon them, such as in the case of 
the translation factor CUGBP1 (Timchenko, Timchenko et al. 1996; Fardaei, 
Larkin et al. 2001; Ho, Charlet et al. 2004).   
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A role for the ZNF9 protein in myotonic dystrophy type 2 
Unlike the prevailing model for myotonic dystrophy, most other nucleotide 
expansion repeat disorders result from the inactivation of one particular gene due 
to the mutated nucleotide repeats.  In Fragile X mental retardation, nucleotide 
expansions are translated in-frame with the FMRP gene, giving rise to a mutated 
form of the protein that lacks endogenous activity (Brown, Jin et al. 2001).  In the 
case of DM2, the tetranucleotide repeat expansion is not translated and while it is 
transcribed, several studies suggest the expansion does not affect RNA stability, 
processing, or export.  These reports, along with a series of review papers, have 
led to the hypothesis that there is no involvement of ZNF9 gene function in the 
progression of the DM2 disease state.  Recent evidence from the Link, Krahe, 
and Timchenko groups has brought this conclusion into question and has 
reignited the study of ZNF9 activity and function in DM2 (Huichalaf, Schoser et 
al. 2009; Sammons, Antons et al. 2010)(R. Krahe, personal communication).   
 
What is the function and activity of the ZNF9 protein? 
 The initial cloning and characterization of the ZNF9 gene suggested that 
ZNF9 may act as a transcription factor for steroid regulated promoters 
(Rajavashisth, Taylor et al. 1989).  Further characterization provided evidence 
that ZNF9 might regulate both transcription and translation through its in vitro 
nucleic acid binding activity (Michelotti, Tomonaga et al. 1995; Pellizzoni, Lotti et 
al. 1997).  In vivo functional analyses were undertaken in multiple systems, but a 
consensus function was never attributed to the protein.  Because of this lack of 
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consensus, the function of the ZNF9 protein in DM2 was never tested.  Gerbasi 
et al showed an in vivo role for the ZNF9 protein, in the process of cap-
independent translation (Gerbasi and Link 2007).  Following up on this 
observation, I determined that ZNF9’s cap-independent translation activity is 
reduced in myoblasts from DM2 patients (Sammons, Antons et al. 2010).  The 
Timchenko group observed that ZNF9 translational targets are downregulated in 
DM2, further suggesting that the in vivo activity of ZNF9 is aberrant, despite 
earlier reports that ZNF9 protein and mRNA levels were normal in DM2 
(Margolis, Schoser et al. 2006).  Additionally, the Krahe group has noted a 
reduction in ZNF9 mRNA and protein levels in a number of DM2 patients (R. 
Krahe, personal communication, manuscript in preparation). Misregulated 
translational control due to ZNF9 loss-of-function would have a profound effect 
on the expression of a large number of proteins in DM2.   
 
Tools for the analysis of ZNF9’s role in DM2 
 Our hypothesis is that ZNF9 is an RNA binding protein that functions as a 
translation factor, and ZNF9 protein levels or activity are misregulated in 
myotonic dystrophy type 2.  As a result, proteins regulated by ZNF9 are expected 
to have aberrant expression.  Gaining more precise knowledge of the proteins 
whose translation is regulated by ZNF9 is critical in understanding the 
contribution of ZNF9 to DM2 and the distinct molecular mechanisms and cellular 
pathways that cause the DM2 disease state. The overarching question of this 
work asks what are the changes in protein expression in myotonic dystrophy type 
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2 compared to the non-disease state.  Does a decrease in ZNF9 expression 
underlie the disease mechanism of DM2?   
 In the following chapter, we sought to analyze the expression of ZNF9 
protein in newly developed mouse models for myotonic dystrophy.  In 
collaboration with Ralf Krahe’s group at the University of Texas Health Sciences 
Center and the Darryl Pappin’s group at Cold Spring Harbor Laboratory, we 
assessed protein expression changes in the skeletal muscle from these new 
mouse models using quantitative mass spectrometry.  These newly developed 
tools and experimental strategies discussed in this chapter, along with the results 
presented here, should be directly applicable and relevant to the study of ZNF9’s 
function in myotonic dystrophy type 2.   
 
Materials and methods 
 
Western blotting 
Whole cell lysates from mouse skeletal muscle were lysed on ice for 30 
minutes using standard RIPA buffer (50mM TRIS, 150mM NaCl, 0.1% SDS, 
0.5% sodium deoxycholate, 1% Triton X-100, 1 Roche EDTA-free mini Protease 
inhibitor tablet/mL). Whole cell lysates were centrifuged at 16,5000 rpm for 15 
minutes at 4C to pellet insoluble fractions.  Soluble protein was assayed for 
protein concentration using the BCA assay method.  50μg of cellular protein were 
fractionated by SDS-PAGE analysis using 10% BisTRIS polyacrylamide gels 
(Novex, Invitrogen) and transferred to nitrocellulose for western blotting analysis.  
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Polyclonal ZNF9 antibodies were previously described (Sammons, Antons et al. 
2010).  GAPDH antibodies (Millipore) were used at 1:5,000 concentration.  
Antibodies were diluted in 1X TBST and 5% non-fat dry milk.   
 
Myotonic dystrophy type 2 mouse models 
The Krahe laboratory has generated a knockin mouse model (DM2-
CCTG-KI) containing a (CCTG)189 expansion in the first intron of the mouse znf9 
gene, which mimics the causative mutation resulting in DM2 in humans (R. 
Krahe, unpublished data).  The original transgenic knockin mouse was created 
by injection of a neo cassette with the (CCTG)189 expansion targeting the 1st 
intron of znf9.  The neo cassette was flanked with loxP sites, and the cassette 
was removed by cre-mediated recombination.  Both the DM2-ZNF9ki-neo and 
DM2-CCTG-KI mice are viable and recapitulate the major features of DM2 (R. 
Krahe, personal communication).  A DM2tgCCTG transgenic line was created 
that expresses 121 CCTG repeats within the first intron of the human skeletal 
actin gene (R. Krahe, unpublished data).  The DM1tgCTG mouse line was a gift 
of Dr. Charles Thornton.  It expresses 250 CTG repeats in the 3’UTR of the 
human skeletal actin gene (Osborne, Lin et al. 2009).    
 
Isolation and processing of mouse skeletal muscle 
Mouse skeletal muscle was stored at -80C until used.  Muscle was cut into 
1-2mm pieces using a clean razor blade and placed into a 2.0mL eppendorf tube.  
250uL of 100mM triethylammonium biocarbonate and 250uL of  
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2,2,2-trifluoroethanol were added to the tube.  Muscle tissue was solubilzed by 
3X-1 min sonication steps (power 2, micro tip) with 1 min of rest on ice between 
each round.  Tubes were then shaken at 1600rpm for 1 hr at 60C, followed by 
another round of sonication.  The tubes were then spun at 165000 rpm for 15 min 
at room temperature in a microcentrifuge to pellet all insoluble protein.  Soluble 
protein was removed and analyzed for protein concentration using the BCA 
assay method.  100ug of protein was reduced with 10mM DTT for 10 min at 60C 
and alkylated with iodoacetemide for 30 min at 30C.  Samples were then 
digested overnight at 37C with sequencing grade trypsin (Promega).  Peptides 
were then snap-frozen in liquid nitrogen and stored at -80C until mass 
spectrometry analysis.   
 
Quantitative mass spectrometry analysis 
Desalted and trypsinized peptides were labeled using the iTRAQ 4-plex 
labeling kit (Applied Biosystems) according to previously published protocols 
(Ross, Huang et al. 2004).  Labeled peptides were then pooled and analyzed by 
LC-MS/MS using a quadropole-time of flight mass spectrometer (Q-TOF) by the 
Cold Spring Harbor Laboratories Proteomic Facility (Cristian Ruse and Darryl 
Pappin).  Peptides and proteins were identified by searching the acquired mass 
spectrometry data against the mouse protein database using the MASCOT 
algorithm (Perkins, Pappin et al. 1999).  Peptide abundance measurements were 
derived from the iTRAQ reporter ions using the SCAFFOLD program (Lundgren, 
Martinez et al. 2009; Searle 2010).       
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Results 
 
ZNF9 protein expression in murine models of myotonic dystrophy 
 Previous models of myotonic dystrophy express expanded nucleotide 
repeats in the 3’UTR of the HSA gene or rely on knockout of downstream 
pathways to mimic the DM1 state (Mankodi, Logigian et al. 2000; Seznec, 
Agbulut et al. 2001).  These models do not take into account the molecular and 
cellular pathways affected by expression of CCUG expanded repeats within the 
context of the znf9 gene.  There have been no investigations into the expression 
of ZNF9 protein in response to a DM2-like expansion in mice.  In collaboration 
with Ralf Krahe’s lab (University of Texas Health Sciences Center at Houston), 
we undertook an analysis of ZNF9 protein expression levels in the skeletal 
muscle of mice with 189 CCTG repeats in the first intron of the mouse znf9 gene.  
A second model mouse line, expressing the expansion along with a loxP-flanked 
neomycin cassette, was analyzed in parallel.  Control mice were litter, age, and 
sex matched.  Whole cell lysates from the thigh skeletal muscle of matched mice 
were analyzed by SDS-PAGE and western blotting for ZNF9 protein expression.  
Western blot analysis for GAPDH was used as a control for protein loading.  As 
seen in Figure 13, ZNF9 protein levels are slightly reduced in DM2-CCTG-KI 
muscle compared to controls (22% reduction, as measured by densitometry).  
ZNF9 protein expression in unfloxed DM2-CCTG-KI muscle is severely reduced 
compared to wild-type control muscle, indicating that the presence of the neo 
cassette affects ZNF9 expression.  This result is likely due to transcription of the 
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neo gene on the opposite orientation across the znf9 transcription start site (R. 
Krahe, personal communication).  Interestingly, the decrease in ZNF9 protein 
expression in DM2-CCTG-KI muscle is similar to the decreases in ZNF9 
expression in myoblasts from DM2 patients (R. Krahe, personal communication; 
manuscript in review), suggesting that expansion of CCUG nucleotide repeats 
within the first intron of znf9 reduces the level of ZNF9 protein (Huichalaf, 
Schoser et al. 2009; Sammons, Antons et al. 2010).  While the exact molecular 
mechanism(s) for the reduction in ZNF9 protein expression is unknown, it is likely 
due to the expanded CCTG repeat in the context of the 1st intron of the znf9 gene 
misregulating the processing of znf9 transcripts.   
 In order to test the hypothesis that the reduction in ZNF9 levels is 
attributed to the CCTG expansion within the first intron of znf9, another set of 
mouse models were developed.  The new transgenic line expresses 121 CCTG 
repeats in the first intron of the HSA gene, analogous to the DM1 model mouse 
with 250 CTG repeats in the 3’UTR of the HSA gene.  These mice can be used 
to directly test whether the genomic context of the nucleotide repeat expansion 
(znf9, dmpk, or another gene) is important for disease progression.  We 
specifically wanted to understand whether expression of CTG or CCTG 
expansion RNA alone would result in decreased ZNF9 protein expression in 
skeletal muscle.  Western blot analysis of skeletal muscle tissue lysates from 
control, DM1tgCTG or DM2tgCCTG mice is shown in Figure 13B.  ZNF9 protein 
levels are consistent across all samples relative to GAPDH controls.  These data 
strongly suggest that a reduction in ZNF9 protein levels in DM2 patients is likely 
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due to the genomic location of the CCTG expansion and not the presence of 
CCUG or CUG nuclear RNA foci proposed in the RNA gain of function model.   
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FIGURE 13 
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Figure 13. Western blot analysis of skeletal muscle from mouse 
models of myotonic dystrophy.  A. Western blot analysis of ZNF9 and 
GAPDH levels in control and DM2 CCTG KI mice (see Materials and 
Methods).  B.  Western blot analysis of ZNF9 and GAPDH levels in 
control and DM1tgCTG or DM2tgCCTG (see Materials and Methods).  
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Quantitative proteomic analysis of protein abundance in myotonic 
dystrophy mouse models 
 
 In order to develop effective therapies and treatments for the myotonic 
dystrophies, it is critical to fully understand the cellular and molecular pathways 
perturbed in the disease state.  Very little is known about the differences in gene 
expression in DM2 and non-affected individuals.  Gene expression analysis of 
myotonic dystrophy has focused on the missplicing events due to decreased 
MBNL expression or changes in mRNA expression due to expression of CTG 
repeats (Osborne, Lin et al. 2009; Du, Cline et al. 2010).  Most previous analyses 
looked specifically for changes in splicing patterns or mRNA abundance in DM1 
mouse models.  Here, we perform an unbiased quantitative mass spectrometry-
based proteomic analysis to measure protein abundance changes in various 
mouse models of myotonic dystrophy.  We chose to use the iTRAQ method for 
quantitative proteomics because it labels proteins after lysis of cells or tissues, 
unlike other metabolic labeling techniques like SILAC (Farley and Link 2009).  
Skeletal muscle tissue (quadriceps) from age, sex, and litter-matched mice was 
processed for iTRAQ labeling and mass spectrometry analysis as discussed in 
Materials and Methods.   
As is common in large gene expression data sets, a method for statistical 
analysis is needed to identify proteins that are likely to be relevant.  For each 
group comparison, we expressed changes in protein abundance as a ratio of the 
calculated protein abundance score in the experimental sample versus the score 
of the control sample.  By converting all measurements to a ratio of experimental 
to control samples, we focused on relative abundance between samples.  The 
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resulting values were then converted to log2 and a group mean score was 
computed for all identified proteins in that comparison.  The standard deviation of 
each group was calculated and any protein with a ratio outside 2 standard 
deviations of the mean, either positively or negatively, was considered significant.   
 
Comparison of DM2-CCTG-KI and wild-type control muscle 
We were interested in measuring the protein abundance changes in DM2-
CCTG-KI mouse skeletal muscle because we believed this model to be the most 
relevant to the actual human disease.  Abundance measurements for 369 
different proteins were obtained in this analysis.  A total of 8 proteins, listed in 
Figure 14B, were upregulated over 2 standard deviations from the mean 
abundance in DM2-CCTG-KI skeletal muscle compared to wild-type muscle.  
The protein showing the largest increase in abundance between samples was 
the heavy chain of immunoglobulin class G (IgG-HC) (Figure 14B), which is 
significantly upregulated in DM2-CCTG-KI mouse muscle.  Patients with 
myotonic dystrophy have reduced levels of serum IgG (hypoglobulinemia), but 
levels of IgG in the muscle are unknown (Nakamura, Kojo et al. 1996).  The 
protein FHL3 is also upregulated in mouse models of cardiomyopathy and is 
specifically expressed in cardiac and skeletal muscle subtypes (Chu, Ruiz-
Lozano et al. 2000).  FHL3 overexpression in skeletal muscle progenitors 
suppresses myotube formation and may lead to decreased muscle regeneration 
(Cottle, McGrath et al. 2007; Meeson, Shi et al. 2007).  Finally, the adipocyte 
fatty acid binding protein (FABP4) was found in significantly higher abundance in 
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DM2-CCTG-KI mouse muscle than in controls.  Despite its name, FABP4 is 
normally expressed in skeletal muscle and increased expression of FABP4 
suppresses normal muscle contraction in rats (Lamounier-Zepter, Look et al. 
2009).  It is tempting to speculate that these upregulated proteins directly 
contribute to the skeletal and cardiac muscle phenotypes seen in patients with 
myotonic dystrophy type 2.    
 Identifying proteins that are less abundant in DM2-CCTG-KI mice than 
wild-type controls can provide significant insight into the molecular mechanisms 
that are absent in DM2.  In our analysis, expression of 6 proteins was 
significantly reduced in DM2-CCTG-KI mice, as shown in Figure 14B.  Of 
particular interest is Troponin T, which is the most significantly reduced protein in 
our analysis.  Troponin T is an essential protein responsible for contraction of 
skeletal and cardiac muscle (Gerhardt and Ljungdahl 1998).  Most importantly, 
Troponin T mRNA is a direct target of MBNL and CUGBP1, and Troponin T 
missplicing gives rise to a large, inactive isoform of Troponin T in the skeletal and 
cardiac muscle of adult myotonic dystrophy patients (Philips, Timchenko et al. 
1998).  Unfortunately, the peptides identified by mass spectrometry do not 
distinguish between the two isoforms.  This result suggests that perhaps 
additional misregulation of troponin T contributes to myotonic dystrophy.  Further 
examination into troponin T protein expression in the myotonic dystrophies is 
warranted.   
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FIGURE 14 
 
 
 
 
 
Figure 14. Quantitative proteomic analysis of protein abundance in 
DM2-CCTG-Knockin mice versus controls.  A. Abundance values for 
each identified and quantified protein displayed as log2( DM2-CCTG-KI 
score/Control score).  The inset table displays the average abundance value, 
the standard deviation, and the values used as a cutoff to determine 
significance for enriched and depleted proteins. The average abundance 
value of all proteins discovered is represented by the dotted line.  B.  Table 
of proteins that were enriched or depleted over 2 standard deviations from 
the mean abundance.   
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Proteomic analysis of skeletal muscle from DM2tgCCTG and DM1tgCTG 
mice 
 
 A direct comparison between DM1 and DM2 using gene expression 
analysis has not yet been reported in the literature.  Most analyses focus on the 
different models or tissue types from one particular disease (Osborne, Lin et al. 
2009; Du, Cline et al. 2010).  We sought to use mouse models of DM1 and DM2 
to analyze protein abundance changes in the skeletal muscle in response to 
nucleotide repeat expansions in unrelated genes.  First, we compared the protein 
abundance changes in the DM2tgCCTG mouse, which expresses 121 CCTG 
repeats in the first intron of the HSA gene, to wild-type control muscle.  
Unfortunately, while these data cannot be directly compared to the DM2-CCTG-
KI model with any statistical significance, we can still observe general trends in 
protein abundance changes between the two DM2 models.  The most striking 
difference between the data is the downregulation of FABP4 in DM2tgCCTG 
mice, which was upregulated in DM2-CCTG-KI mice compared to controls.  
These particular experiments were not set up to measure absolute protein 
abundance.  Nonetheless, there is a marked reduction in FABP4 relative to 
control samples in the DM2tgCCTG muscle.  I hypothesize that the difference 
between the expression of FABP4 in the two mouse models lies in the genomic 
context of the CCTG nucleotide expansion.  Additional experiments, such as an 
alternative means to measure absolute protein concentrations, are needed to 
better understand this result.  Ideally, the two mouse models would be analyzed 
in the same experiment, allowing us to elucidate relative changes in protein 
abundance between the two models. 
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 Not surprisingly, many of the protein expression changes between the 
DM2tgCCTG mouse and control are complementary.  For example, PRKAB2, an 
AMPK regulatory subunit, has higher protein abundance in DM2tgCCTG muscle 
than in controls, while proteins such as HSD17B10 and ALDH6A1 show lower 
expression.  Increased PRKAB2 expression is implicated in the shutdown of 
cholesterol and fatty acid synthesis, while HSD17B10 and ALDH6A1 are both 
critical enzymes within these synthesis pathways (Vasiliou and Pappa 2000; Iseli, 
Walter et al. 2005; Yang, He et al. 2005).  AMPK signaling is also implicated in 
metabolic and oxidative stress, which is likely increased in myotonic dystrophy 
(Polekhina, Gupta et al. 2003).  Fittingly, multiple glutathione-S-transferase 
enzymes are upregulated in DM2tgCCTG muscle, suggesting that increased 
oxidative stress may contribute to DM2 pathogenesis.  Lastly, the RPL5 protein, 
regulated translationally by a 5’TOP mRNA sequence and the ZNF9 protein, is 
also downregulated in DM2tgCCTG mice (Pellizzoni, Lotti et al. 1997).  
Previously, the Timchenko group observed that 5’TOP containing mRNAs are 
poorly translated in DM1 and DM2.   They hypothesize that this is caused by 
reductions in ZNF9 activity (Huichalaf, Schoser et al. 2009; Huichalaf, Sakai et al. 
2010).    Taken together, the protein abundance changes between DM2tgCCTG 
muscle and control muscle provide potential clues into the variety of cellular and 
molecular processes that are misregulated in myotonic dystrophy type 2.   
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FIGURE 15 
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Figure 15. Quantitative proteomic analysis of protein abundance in 
DM2tgCCTG mice versus controls.  A. Abundance values for each 
identified and quantified protein displayed as log2( DM2tgCCTGg 
score/Control score).  The inset table displays the average abundance value, 
the standard deviation, and the values used as a cutoff to determine 
significance for enriched and depleted proteins. The average abundance 
value of all proteins discovered is represented by the dotted line.  B.  Table 
of proteins that were enriched or depleted over 2 standard deviations from 
the mean abundance. 
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 The RNA gain of function model for the myotonic dystrophies, if true, 
would predict that similar gene expression signatures would be present in both 
DM1 and DM2.  If radically different patterns of gene expression exist, then the 
two diseases may be caused by different pathogenic mechanisms.   In order to 
examine these possibilities, we analyzed two groups of samples for significant 
changes in protein abundance.  The first group compared DM2tgCCTG muscle 
protein abundance to those of the DM1tgCTG mouse.  The DM2 model 
(DM2tgCCTG) showed significant upregulation (>2 SD) of a number of glycolytic 
enzymes and proteins involved in cellular energy production compared to the 
DM1 model (Figure 16B).  DM2tgCCTG muscle showed significant 
downregulation of Cma1, also known as mast chymase, which has 
antiproliferative activity in rat cardiomyocytes(Hara, Matsumori et al. 1999).  
Satellite cells from DM1 patients were previously shown to display reduced 
proliferative capacity compared to DM2 myoblasts (Pelletier, Hamel et al. 2009).  
The lack of a large number of significant differences between the DM2tgCCTG 
and DM1tgCTG transgenic mice is not suprising, as the two diseases are very 
similar.  Additionally, the nucleotide expansions are not in their proper cellular 
context (the znf9 and dmpk genes, respectively) and does not account for gene-
specific effects of the expansions.  Expanded repeats of CCTG and CTG are 
predicted to adapt very similar secondary structure and both are found in nuclear 
foci in DM2 and DM1, respectively.  These observations strongly suggest that the 
RNA-mediated cellular toxicity is especially relevant to these particular mouse 
models. 
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FIGURE 16 
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Figure 16. Quantitative proteomic analysis of protein abundance in 
DM2tgCCTG mice versus DM1tgCTG mice.  A. Abundance values for 
each identified and quantified protein displayed as log2( DM2tgCCTG 
score/DM1tgCTG score).  The inset table displays the average abundance 
value, the standard deviation, and the values used as a cutoff to 
determine significance for enriched and depleted proteins. The average 
abundance value of all proteins discovered is represented by the dotted 
line.  B.  Table of proteins that were enriched or depleted over 2 
standard deviations from the mean abundance. 
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 A comparison of the similarities and differences between DM2tgCCTG 
and DM1tgCTG transgenic mouse skeletal muscle protein abundance could yield 
important cellular pathways that are disrupted in both DM1 and DM2 patients.  
Indeed, compared to wild-type control animals, expanded repeat expression 
results in a significant upregulation of a number of proteins involved in the 
cellular response to oxidative stress, like the glutathione-s-transferases.  As 
muscles age and become damaged, reactive oxygen species (ROS) are 
produced and are neutralized by enzymes like the glutathione-s-transferases 
(Rossi, Marzani et al. 2008).  Upregulation of enzymes to combat ROS during 
muscle damage and aging is common, and is likely a possible therapeutic target 
for muscle regeneration (Jackson 2009).  Additionally, mouse muscle expressing 
expanded repeats shows significant and increased expression of decorin, a small 
proteoglycan, that is associated with actively regenerating muscle (Li, Li et al. 
2007).  Overall, these data support the notion that mouse models for myotonic 
dystrophy type 1 and type 2 share similar gene expression patterns that indicate 
damaged or aging muscle, but that differences between the two expression 
patterns may explain some of the differences between DM1 and DM2.   
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FIGURE 17 
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Figure 17. Quantitative proteomic analysis of protein abundance in 
DM2tgCCTG and DM1tgCTG mice compared to wild-type controls.  A. 
Abundance values for each identified and quantified protein displayed as 
log2( Average of DM2tgCCTGscore and DM1tgCTG score / Average of Wild-
type controlsscore).  The inset table displays the average abundance value, 
the standard deviation, and the values used as a cutoff to determine 
significance for enriched and depleted proteins. The average abundance 
value of all proteins discovered is represented by the dotted line.  B.  Table 
of proteins that were enriched or depleted over 2 standard deviations from 
the mean abundance. 
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Discussion 
 In this chapter, I undertook a quantitative proteomic analysis of skeletal 
muscle from mouse models of myotonic dystrophy types 1 and 2.  The goal of 
this work was to better understand the changes induced by expanded nucleotide 
repeats on gene expression, specifically within the znf9 gene.  Three mouse 
models for myotonic dystrophy were used to assess the changes in protein 
abundance in response to nucleotide repeat expansions, including a never-
before-used knock-in model that expressed CCTG repeats within their proper 
cellular context.  
Comparison of the protein abundance changes between the DM2-CCTG-
KI mouse and its wild-type control revealed that a protein (troponin T) previously 
known to be misregulated in DM2 is reduced in the disease state.  Follow-up 
experiments examining the protein expression of different troponin T isoforms, 
specifically the isoforms found in DM2 (those containing exon 5), will provide 
additional insight into the mechanism of myotonic dystrophy (Philips, Timchenko 
et al. 1998).  All protein expression changes should be validated using other 
techniques, such as western blotting if appropriate antibodies are available.  In 
cases where specific antibodies are unavailable, as is the case with many 
alternatively spliced protein isoforms, targeted proteomics approaches can be 
used.  Methods like selected reaction monitoring (SRM) take advantage of 
isotopically-labeled peptides and can provide absolute quantification of almost 
any peptide or protein (Lange, Picotti et al. 2008; Picotti, Bodenmiller et al. 2009).   
 108
For example, an absolute quantification analysis of the adult and embryonic 
alternatively spliced troponin T isoforms would provide a clearer picture into the 
role of this protein (Philips, Timchenko et al. 1998; Seznec, Agbulut et al. 2001). 
SRM experiments are especially applicable to the analysis of proteins, like ZNF9, 
where there have been controversial reports on the actual abundance of the 
protein within DM2, because the technique is unbiased with respect to 
antibody:antigen binding (Margolis, Schoser et al. 2006).   
While a large number of proteins showed changes in protein expression in 
this analysis, we focused only on those whose expression changed more than 2 
standard deviations from the average protein abundance in order to target the 
largest differences between samples.  The proteins with large changes between 
samples are those likely to be important in the molecular events that lead to or 
sustain myotonic dystrophy-like symptoms.  Large changes, though, are not 
necessarily the most significant to the disease.  In fact, extremely small 
perturbations in protein expression can result in large physiological changes.  
Increasing the number of experimental replicates would allow for the use of more 
sophisticated statistical analysis methods, such as those commonly used for 
microarray data analysis (Eisen, Spellman et al. 1998; Pan 2002).  Analyses 
such as these would allow us to pick out small, but statistically significant, 
changes in protein abundance important for myotonic dystrophy disease 
progression.   
The use of mass spectrometry-based proteomics to assess changes in 
protein expression is widely-used, but the design of many the experiments do not 
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allow for the assessment of the mechanism of these changes in protein 
abundance.  For example, although we report a number of protein abundance 
changes in myotonic dystrophy mouse models, we do know whether the protein 
expression changes at the level of transcription, RNA processing, translation, or 
protein stability.  Experiments combining mass spectrometry-based proteomics 
and genomic strategies, such as microarray or RNAseq should be used to better 
understand the mechanism behind such changes.  This is especially applicable 
to the study of myotonic dystrophy because of the hypothesized roles of splicing 
and translation in the disease mechanism (Philips, Timchenko et al. 1998; 
Huichalaf, Schoser et al. 2009; Huichalaf, Sakai et al. 2010; Sammons, Antons et 
al. 2010).   
Mice with reduced expression of either ZNF9 or DMPK develop symptoms 
directly mimicking the myotonic dystrophies, indicating that these genes are likely 
misregulated in the diseases (Jansen, Groenen et al. 1996; Reddy, Smith et al. 
1996; Chen, Wang et al. 2007).  The newly-developed model for DM2, the DM2-
CCTG-KI mouse, will be an extremely valuable tool for determining the role of 
genomic context in the development of the myotonic dystrophies.  Comparing the 
physiological, cellular, and molecular changes in this animal compared to 
animals expressing CCTG repeats in an unrelated gene will provide critical 
information into the molecular mechanism of DM2.  Likewise, using a context-
sensitive DM1 model alongside animals expressing CTG repeats from a 
transgene will help elucidate signaling and cellular pathways involved in DM1.  In 
the future, mice with reduced ZNF9 and DMPK expression should be included in 
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any analysis of DM2 and DM1 molecular mechanisms.  These mouse models will 
be critical in either further supporting the RNA toxicity model or revealing a 
context-dependent mechanism for the disease.  Only more time and more effort 
will allow us to reveal the complex mechanism underlying the myotonic 
dystrophies.    
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CHAPTER V 
 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS  
 
 This dissertation investigated the function of the ZNF9 protein and its role 
in the human disease myotonic dystrophy type 2.  In this chapter, I will analyze 
the significance of my findings and discuss their relevance to the study of 
myotonic dystrophy and the overall field of molecular biology.  I will discuss what 
my work has contributed to the scientific world and propose other experimental 
strategies that would be beneficial to researchers following-up on this work.  
 
ZNF9 activates cap-independent translation of the ODC IRES  
 Over 20 years since its initial cloning and characterization, the function of 
the human protein ZNF9 is unclear (Rajavashisth, Taylor et al. 1989).  The initial 
aim of my dissertation research was to identify and validate the function of this 
protein, as its importance is underscored by its involvement in the disease 
myotonic dystrophy type 2.  My work has led to a newly published report on 
ZNF9’s in vivo function (Sammons, Antons et al. 2010). This report, along with 
other evidence presented in this dissertation, indicates that ZNF9 functions as an 
internal ribosome entry site trans-acting factor, or ITAF.  Previous evidence, 
especially studies from the laboratory of Paola Pierandrei-Amaldi and the 
graduate work of Vincent Gerbasi, suggested that ZNF9 may function as a 
translation factor, and my work continued this line of inquiry.   
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 Vincent Gerbasi and Andrew Link noted that overexpression of the ZNF9 
protein activated cap-independent translation of a reporter gene fused to the 
5’UTR of the rat ornithine decarboxylase mRNA (Gerbasi and Link 2007).  I 
initially began my work trying to ascertain how ZNF9 might perform such a 
function.  From previous work, ZNF9 was known to associate with the La protein 
and PCBP2, both known ITAFs, on different mRNA substrates (Pellizzoni, Lotti et 
al. 1997; Pellizzoni, Lotti et al. 1998; Gerbasi and Link 2007), but it was unknown 
if ZNF9 directly interacted with mRNA or required an adaptor protein.  We 
focused specifically on the 5’UTR of the human ODC mRNA as a target site, as 
we were interested in the function of the ZNF9 protein in humans because of its 
relationship to DM2.  ZNF9 specifically binds to a 45bp RNA sequence from the 
ODC 5’UTR, and does so independent of other proteins (Sammons, Antons et al. 
2010).  This data suggested that ZNF9 might associate with the translation 
machinery, which was confirmed by polysome profiling, cosedimentation 
analysis, and ribosome salt wash experiments (Sammons, Antons et al. 2010).  
Using a bicistronic reporter system, I discovered that ZNF9 activates cap-
independent translation through the human ODC IRES (Sammons, Antons et al. 
2010).  Data presented in Chapter III on a potential ZNF9 homolog indicates that 
the ribosome interactions are evolutionarily conserved, indicating that ZNF9 is 
likely a bona fide translation factor.  Taken together, these data strongly suggests 
that ZNF9 acts as an ITAF in vivo.   
 Work from the laboratory of Lubov Timchenko (Baylor College of 
Medicine) bolsters the hypothesis that ZNF9 acts to regulate translation through 
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interaction with 5’ untranslated regions.  In a series of UV crosslinking 
experiments, ZNF9 was found to associate with the 5’UTRs of a number of 
mRNAs involved in the regulation of translation (Huichalaf, Sakai et al. 2010), 
and that knockdown of ZNF9 expression reduces the incorporation of S35 into 
actively synthesizing peptides (Huichalaf, Sakai et al. 2010).  Interestingly, the 
mRNAs studied all encode either ribosomal protein subunits or translation 
factors.  It would be interesting if ZNF9, in addition to its ability to activate cap-
independent translation of human ODC, could facilitate the synthesis of certain 
translation factors through cap-dependent mechanisms.  Regulating translation 
through controlling the synthesis of the translation machinery is not uncommon 
(Tang, Hornstein et al. 2001; Guertin, Guntur et al. 2006), and this possibility 
needs to be investigated further to better understand how ZNF9 controls cellular 
protein synthesis.   Taken together, the work presented in this dissertation and 
from the Timchenko group clearly indicates that ZNF9 binds to the 5’UTR of 
multiple mRNAs and is involved in the regulation of translation.   
 
Potential mechanisms of ZNF9 mediated cap-independent translation 
activation 
 
 The full scope of the cellular interactions and mechanisms by which ZNF9 
activates cap-independent translation are unclear, but work presented in 
Chapters II and III provide some intriguing details.  ZNF9 directly binds to the 
ODC mRNA independent of other cofactors, but whether ZNF9 can activate cap-
independent translation independent of other ITAFs is unknown.  
Coimmunoprecipitation experiments show that ZNF9 associates with the ITAFs 
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La and PCBP2, and that other ITAFs, such as UNR and polypyrimidine-tract 
binding protein (PTB), can bind to the ODC IRES (Gerbasi and Link 2007).  
Because these proteins are all known ITAFs, it was initially postulated that ZNF9 
may be part of an ITAF complex that acts together to activate cap-independent 
translation.  The initial screen that identified ZNF9 as a putative ITAF provides 
clues into the requirement for other proteins during IRES activation.  ZNF9 and 
PCBP2 interacted with only the wild-type IRES sequence, but UNR and PTB 
interacted with both the wild-type sequence and a mutant sequence that does not 
support internal ribosome entry (Pyronnet, Pradayrol et al. 2000; Gerbasi and 
Link 2007).  This suggests that the loss of either ZNF9 or PCBP2 binding to the 
wild-type IRES stops cap-independent translation from the ODC IRES.  Because 
ZNF9 directly binds to the wild-type internal ribosome entry site of the ODC 
5’UTR, it is likely that ZNF9 itself is a central regulator of cap-independent 
translation.  The roles for the other members of this potential ITAF complex in 
ODC IRES regulation are unknown, but both UNR and PTB have been shown to 
repress cap-independent translation during mitosis, when the ODC IRES is most 
active (Pyronnet, Pradayrol et al. 2000; Schepens, Tinton et al. 2007).  PTB and 
UNR may act to repress ODC translation by blocking ZNF9 access to their 
shared binding sites.   
The main question remaining is how ZNF9 binding to an IRES recruits the 
ribosome and activates translation.  Association of ZNF9 with the translation 
machinery is dependent upon actively translating polysomes.  The putative 
ortholog Gis2p shows reduced ribosome association when polysomes are 
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treated with RNAse A, suggesting that the protein requires intact mRNA to 
associate with the ribosome.  This is similar to what is seen for other translation 
factors, like FMRP (Tamanini, Meijer et al. 1996; Feng, Absher et al. 1997), 
suggesting that ZNF9 may first associate with an mRNA and then recruit the 
ribosome through an unknown mechanism.  Other activators of IRES-dependent 
translation are believed to act as RNA chaperones and induce conformational 
changes in RNA secondary structure which are then recognized by the ribosome 
(Song, Tzima et al. 2005).  This particular mechanism is mainly speculative, but 
would make sense based upon the mechanisms of viral IRES function.  Viral 
IRESs activate translation almost entirely through RNA secondary structures that 
mimic rRNA or tRNA (Fraser, Hershey et al. 2009).  It is possible that ITAFs bind 
to specific sequences and then induce those RNA sequences to adapt a certain 
structure which causes ribosome recruitment, but this has not been directly 
shown by experimental methods.  Interestingly, ZNF9 is a known nucleic acid 
chaperone and could fulfill this role during IRES-mediated translation (Armas, 
Nasif et al. 2008).  Structural studies of the interaction of ZNF9 and the ODC 
IRES would provide unequivocal evidence of these putative RNA chaperone 
activities and IRES conformational changes.   
 
Future directions for the study of ZNF9 function and cap-independent 
translation 
 
Future investigations into the mechanism of ZNF9’s activity as an activator 
of cap-independent translation are likely given the proteins role in myotonic 
dystrophy type 2.  The most pressing needs for ZNF9 biology are further 
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elucidation of the mechanism of RNA binding and ribosome recruitment and the 
discovery of novel mRNA targets.  The mechanistic details of internal ribosome 
entry site mediated translation of viral mRNAs are far ahead that of cellular 
eukaryotic mRNAs, and the study of ZNF9 provides the opportunity to shore up 
our understanding of eukaryotic cellular IRES biology.  To study the interaction 
between ZNF9 and the ribosome, a series of deletion mutants similar to those 
shown in Chapter III should be tested for their ability to bind to the ODC IRES 
and associate with the translating ribosome in an in vitro system.  Mutations that 
reduce either RNA binding or ribosome association are very likely to reduce 
IRES activation.  As previously mentioned, structural studies (X-ray 
crystallography, NMR) probing the ZNF9:ODC IRES interaction are especially 
warranted, given the lack of information on structural rearrangements in cellular 
IRESs.  Experiments such as these are straightforward, but are likely to provide a 
wealth of insight into the function of ZNF9 and the function of cellular IRES-
mediated translation. 
It is highly probable that ZNF9 regulates the translation of additional 
cellular mRNAs beyond those currently known.  Identification of these mRNAs 
will provide additional information into the cellular pathways regulated by ZNF9.  
The use of a RIP-CHIP or RIP-RNASeq experimental strategy can be used to 
identify mRNAs that associate with ZNF9 (Brown, Jin et al. 2001; Tenenbaum, 
Lager et al. 2002).  Isolation of ZNF9 from relevant tissues, such as skeletal 
muscle, would coprecipitate interacting mRNAs, allowing for their identification by 
microarray or next-generation DNA sequencing.  While these experiments can be 
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performed, they are still biased by the ability of the researcher to isolate ZNF9 
efficiently and to isolate potentially transient RNA interactions.  Alternatively, a 
polyribosome profiling approach can be used to identify mRNAs that are 
translated in the presence and absence of the ZNF9 protein.  Ideally, cell lines 
completely lacking ZNF9 would be used for this purpose, but cell lines with 
reduced expression of the protein of interest have been used in the past for this 
purpose (Marash, Liberman et al. 2008).  While the immunoprecipitation 
approach is preferred due to the smaller amount of data analysis required, both 
approaches are valid and can and should be used to identify mRNA targets of 
ZNF9.  Identification of additional mRNA targets of ZNF9 has direct relevance to 
the study of myotonic dystrophy, as decreased ZNF9 activity would reduce 
translation of these targets, which may cause some of the observed pathologies 
in the disease.     
 
The regulation of ZNF9 and its activity are aberrant in DM2 
 The most intriguing, and arguably most important, finding of this 
dissertation is that ODC IRES-dependent translation is reduced in DM2 
myoblasts due to a decrease in ZNF9 expression.  Previous mechanistic models 
for the myotonic dystrophies completely discounted the role of ZNF9 (and DMPK) 
gene activity in the pathogenesis of the disease.  In this work, I determined that 
ZNF9 mRNA expression is reduced approximately 30% in myoblasts from a DM2 
patient and that the activity of ZNF9 is also reduced (Sammons, Antons et al. 
2010).  Recent publications from the Timchenko lab further this observation, as 
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they observe reduced ZNF9 protein levels and aberrant protein localization in 
DM2 myoblasts (Huichalaf, Sakai et al. 2010).  Additionally, the Krahe and Udd 
labs, in a survey of mature skeletal muscle from DM1 and DM2 patients, saw a 
marked reduction in ZNF9 protein expression in DM2 patients (R. Krahe, 
personal communication), further bolstering the hypothesis that ZNF9 protein 
expression is reduced in DM2.  Of course, a reduction in a given proteins 
expression in a disease state does not necessarily implicate the function of that 
protein the underlying mechanism of that disease.  Evidence for a direct role of 
decreased ZNF9 activity came from the lab of Yi-Ping Li, where mice with one 
copy of the znf9 gene show late-onset muscle wasting, cataract formation, and 
cardiac arrhythmias, all symptoms of human patients with DM2 (Chen, Wang et 
al. 2007).  These data, taken together, suggest that ZNF9 protein expression and 
activity are likely components of the DM2 disease mechanism.   
 
Discrepancies in the RNA gain-of-function model 
The prevailing model, RNA gain-of-function, suggests that stable CUG or 
CCUG RNA repeats are retained in “nuclear foci” and sequester essential cellular 
proteins whose subsequent misregulation causes both myotonic dystrophy type 1 
and type 2.  The model was initially developed because of these RNA foci and to 
explain the very similar clinical manifestations of DM1 and DM2.  This model is 
supported by a large body of literature and certainly explains a large number of 
the molecular observations and clinical features of the disease.  It should be said 
that the large majority of the work in the field has focused on the more prevalent 
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DM1.  Unfortunately, there are still quite a few discrepancies between the 
proposed model and the observed data (and clinical manifestations), suggesting 
that an important piece is missing.  I propose that the missing piece of the puzzle 
is the effect of nucleotide expansion within the znf9 gene in DM2, and by 
extension, the effect of a nucleotide repeat expansion within dmpk in DM1.  Here, 
I will attempt to combine the disparate data and reconcile the current RNA gain-
of-function model with the observations in this dissertation and in literature.   
 Toxic CUG and CCUG RNA foci are certainly present in DM1 and DM2, 
respectively, and their presence does result in the misregulation of splicing.  
Nuclear repeat RNA sequesters MBNL, reducing the activity and inhibiting the 
splicing of target pre-mRNAs (Fardaei, Larkin et al. 2001; Kanadia, Johnstone et 
al. 2003).  Reduced MBNL activity has been shown to be an important 
component of the myotonic dystrophy disease model, as knockout of the mbnl 
gene phenocopies transgenic mice expressing expanded CTG repeats in the 
3’UTR of the HSA gene (Mankodi, Logigian et al. 2000; Seznec, Agbulut et al. 
2001; Kanadia, Johnstone et al. 2003).  Missplicing and myotonia can be 
rescued by overexpression of MBNL or the use of oligonucleotides that displace 
MBNL from RNA foci (Kanadia, Shin et al. 2006; Arambula, Ramisetty et al. 
2009; Mulders, van den Broek et al. 2009; Mulders, van Engelen et al. 2010), but 
these treatments do not restore other phenotypes associated with DM1 (and 
DM2). These results suggest that although reduced MBNL activity contributes to 
symptoms of myotonic dystrophy, it is not a primary, underlying cause.   
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 CUGBP1 activity is increased in response to expression of expanded 
CUG or CCUG repeat RNA, and significant evidence implicates increased 
CUGBP1 in the development of myotonic dystrophy.  Mice overexpressing 
CUGBP1 in skeletal muscle show severe muscle wasting and cardiac 
abnormalities, and chemical inhibition of PKC, the kinase that activates 
CUGBP1, reduces these effects (Wang, Kuyumcu-Martinez et al. 2009; 
Koshelev, Sarma et al. 2010; Ward, Rimer et al. 2010).  While increased 
CUGBP1 expression and activity underlie a number of myotonic dystrophy 
clinical manifestations, it does not explain all of them, even in combination with 
reduced MBNL levels.   
 An important tool in myotonic dystrophy research has been the use of 
transgenic mouse models for the disease.  The first set of mice expressed CTG 
repeats in the 3’UTR of the human skeletal actin gene and recapitulated many 
disease symptoms (Mankodi, Logigian et al. 2000; Seznec, Agbulut et al. 2001).  
These mice, along with the (at the time) recent discovery that DM2 was caused 
by an expansion of CCUG repeats within the znf9 gene, pointed towards a gene-
independent mechanism for the diseases.  Interestingly, expansion of CTG 
repeats in the 3’UTR of the dmpk gene, the proper genomic context, leads to 
more severe myotonic dystrophy-like symptoms, suggesting that perhaps DMPK 
is involved in the disease mechanism.  To date, no mouse models for DM2 have 
been published, but characterization of the DM2-CCTG-KI mouse discussed in 
Chapter IV is underway and appears to recapitulate DM2 symptoms (R. Krahe 
and B. Udd, personal communication).  
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  Of course, the question of how ZNF9 expression and activity are reduced 
in DM2 remains.  The most obvious, but as-of-yet untested, mechanism would be 
that either transcription or processing of ZNF9 mRNA is reduced due to the 
nucleotide expansion.  Two early reports, looking at myoblasts and transformed 
lymphoblastoid cell lines from DM2 patients, suggested that transcription, mRNA 
processing, and translation are all normal in DM2 (Botta, Caldarola et al. 2006; 
Margolis, Schoser et al. 2006). These results are in striking opposition to work in 
this dissertation and published elsewhere that ZNF9 mRNA and protein levels 
are reduced in DM2 myoblasts.  Only careful analysis of mRNA and protein 
levels in DM2 will resolve these discrepancies.  Another possible mechanism 
involves an interaction of ZNF9 with the expanded CCUG RNA repeat.  Although 
initially thought to be retained solely in the nucleus, the repeat RNA is also found 
in the cytoplasm with ZNF9 (Salisbury, Schoser et al. 2009; Huichalaf, Sakai et 
al. 2010).  ZNF9 and the CCUG RNA do not colocalize by in situ hybridization, 
but this does not rule out a transient interaction, as CUGBP1 interacts with CUG 
and CCUG expansion RNA, but does not colocalize by immunofluorescence.  
Further testing of this mechanism and the reduced ZNF9 expression mechanism 
are warranted in light of these recent findings.   
 
Future directions and experimental strategies for elucidating the 
involvement of ZNF9 in the myotonic dystrophy disease mechanism 
 
 As a result of the data presented here and from the Timchenko laboratory, 
a further experimental investigation into the role played by the ZNF9 protein in 
myotonic dystrophy would be prudent.  Beyond a more careful examination of 
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ZNF9 mRNA expression, processing, and translation in the muscle from DM2 
patients, a number of experiments should be performed.  The first step was 
recently performed, creation of a mouse model for DM2, reported in Chapter IV.  
This mouse (DM2-CCTG-KI) recapitulates the exact genomic expansion seen in 
DM2 patients, with a large CCTG expansion in the first intron of the znf9 gene.  
As seen in Chapter IV, this expansion does cause a small decrease in ZNF9 
protein levels, and the Krahe lab reports decreases in transcription, certain pre-
mRNA species, and ultimately, translation in these mice (R. Krahe, personal 
communication).  The DM2-CCTG-KI mouse can be directly compared to the 
mouse expressing CCTG expansions in the HSA gene, to determine how the 
context of the expansion affects ZNF9 expression and ultimately, myotonic 
dystrophy-like symptoms.  Special care should be taken to make sure that the 
expansions are of a similar size in all comparisons, as larger expansions cause 
more severe symptoms in DM2 patients.  Ultimately, these mice need to be 
compared to the ZNF9+/- mouse reported by the Li group (Forsythe Institute, 
Boston, MA) to determine if ZNF9 functional activity is aberrant in the animals 
expressing the expanded repeats.  A comprehensive gene expression analysis of 
adult mouse skeletal muscle from these three mice would provide a wealth of 
information into the cellular and molecular pathways governing the development 
of myotonic dystrophy.  Unfortunately, these mice are not readily shared by the Li 
group, so these experiments are not likely to be carried out soon.   
 The RNA gain of function model, too, can be directly tested by the use of 
transgenic animals and quantitative proteomics.  If the RNA gain of function 
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model is correct, one would predict that an identical set of proteins are activated 
or sequestered by expression of CUG and CCUG repeats.  Differences in protein 
binding or activity induced by either CUG or CCUG repeats would be expected to 
account for the differences in clinical manifestations of the disease.  A 
quantitative differential proteomics analysis of CUG and CCUG RNA binding 
proteins would provide information into the differences in repeat RNA binding that 
can be predicted to account for differences between DM1 and DM2.  Skeletal 
muscle from adult mice should be used as a source of the RNA binding proteins, 
as this is the most commonly affected muscle type in myotonic dystrophy and 
likely contains proteins that aberrantly regulated due to CUG or CCUG repeats.  
Specific RNA binding proteins can be tested for colocalization or reduced 
function or expression in DM1 or DM2 mouse models to determine if they are 
truly part of the disease mechanism.   
An additional set of mouse models would ultimately determine whether the 
RNA gain of function model is accurate.  It is already known that animals 
expressing either CTG or CCTG expansions in the HSA gene show similar, but 
not identical, myotonic dystrophy-like symptoms, mimicking DM1 and DM2, 
respectively.  Mice expressing identical length CCTG expansions in the 3’UTR of 
dmpk and CTG expansions in the 1st intron of znf9 should be created.  If the RNA 
gain of function model is accurate, the mice should switch phenotypes; mice 
expressing CCTG expansions in dmpk should exhibit more DM2-like phenotypes 
and vice versa.   
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I undertook a quantitative proteomic analysis of various mouse models of 
DM1 and DM2 in order to examine if any changes in protein abundance would 
account for the similarities and differences between DM1 and DM2.  Ideally, 
these experiments will be repeated in DM1 and DM2 context-sensitive mouse 
models (ie those with expansions within dmpk or znf9) to gain the most relevant 
disease-specific data.  Regardless, experiments examining expression (western 
blotting, SRM proteomics) of the significantly up- or downregulated proteins in 
each comparison set should be undertaken as a follow-up to my work.   As 
discussed in Chapter IV, microarray or RNA-Seq-based mRNA abundance 
measurements should be performed in order to attribute changes in protein 
abundance to either transcription or mRNA stability.  Differentially expressed 
proteins whose respective mRNAs show equal expression are likely regulated at 
the level of translation or protein stability.  It would be especially interesting (and 
relevant) to perform a quantitative proteomics analysis on adult skeletal muscle 
from the DM2-CCTG-KI mouse and the ZNF9+/- mouse.  This type of analysis 
would elucidate the changes in protein abundance resulting from CCTG 
expansions and from a loss of ZNF9 function.  A combination of genetic models, 
gene expression analysis, and common molecular biology techniques will reveal 
whether or not ZNF9 protein function is truly aberrant in myotonic dystrophy type 
2.   
 The work and data reported in this dissertation lay the groundwork for the 
continued study of the function of the ZNF9 protein and its role in the 
development of myotonic dystrophy type 2.  Increased focus on the in vivo 
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function of ZNF9 will yield additional knowledge into the still poorly understood 
process of cap-independent translation.  I also describe a potential new model 
system in which to study the function of the ZNF9 protein, which will allow for the 
identification of potential regulatory proteins by high-throughput genetic and 
proteomic technologies.  Finally, I provide an atlas of protein expression changes 
in mouse models for DM2 which may be relevant to the development and 
maintenance of the DM2 disease state.  Ultimately, this dissertation provides a 
clear motivation and framework for future researchers to follow in order to better 
understand the role of ZNF9 in myotonic dystrophy type 2.  Hopefully, we, as a 
scientific community, will solve the complex mechanism of the myotonic 
dystrophies and develop effective treatments for this debilitating disease.    
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APPENDIX A 
 
Table A1 –Protein abundance factors (PAF) from replicate Gis2-Tap 
purifications            
 
Accession 
# Gene 
tot # 
spectra 
tot non-
redun 
spectra 
tot non-
redun 
peptides
# 
unique 
% AA 
covg PAF 
YLR344W RPL26A 138 21 13 3 61.72 14.75341
YGR034W RPL26B 144 19 12 2 53.85 13.00568
YNL255C GIS2 216 20 13 13 74.03 11.69385
YLL045C RPL8B 134 28 20 3 67.32 9.960159
YOR096W RPS7A 373 21 12 6 72.25 9.71233
YKL006W RPL14A 47 14 10 1 61.87 9.230566
YMR194W RPL36A 27 10 7 1 49.5 8.989572
YPL249C-A RPL36B 27 10 7 1 49.5 8.980692
YDL061C RPS29B 22 6 4 4 45.61 8.917955
YNL302C / 
YOL121C ** 
RPS19B 
/ 
RPS19A 139 14 10 0 58.62 8.810018
YNL096C RPS7B 122 19 12 6 60.21 8.782472
YDL136W / 
YDL191W 
RPL35B 
/ 
RPL35A 81 12 9 0 38.84 8.626887
YDL075W RPL31A 270 11 6 1 51.75 8.492241
YGR027C / 
YLR333C ** 
RPS25A 
/ 
RPS25B 59 10 5 0 42.2 8.306338
YKL180W RPL17A 163 17 9 1 50.81 8.272909
YBR031W RPL4A 521 32 17 2 55.37 8.185818
YHL033C RPL8A 106 23 16 1 60.31 8.177778
YHR203C / 
YJR145C 
RPS4B / 
RPS4A 121 24 18 0 48.09 8.16049
YDR382W RPP2B 22 9 6 6 74.77 8.144796
YFR031C-A 
/ YIL018W 
RPL2A / 
RPL2B 194 22 15 0 47.06 8.026853
YML073C RPL6A 77 16 12 6 63.28 8.01563
YDR012W RPL4B 496 31 17 2 55.37 7.936102
YJR094W-A  RPL43B  70 8 6 0 49.46 7.927857
YLR075W RPL10 139 20 17 17 61.71 7.886124
YJL177W RPL17B 143 16 9 1 50.81 7.785509
YLR406C RPL31B 265 10 6 1 51.75 7.711884
YML063W RPS1B 144 22 16 4 59.77 7.635707
YDR450W / 
YML026C 
RPS18A 
/ 
RPS18B 53 13 10 0 61.9 7.630004
YDR447C / RPS17B  105 12 8 0 54.01 7.593495
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Table A1 – Continued 
 
Accession 
# Gene 
tot # 
spectra 
tot non-
redun 
spectra 
tot non-
redun 
peptides
# 
unique 
% AA 
covg PAF 
YDL082W / 
YMR142C 
** 
RPL13A 
/ 
RPL13B 115 17 13 0 51.5 7.537466
YLR448W RPL6B 88 15 10 4 55.93 7.505254
YBL092W RPL32 41 11 8 8 49.62 7.447025
YGL147C RPL9A 67 16 10 1 59.9 7.418054
YLR441C RPS1A 140 21 15 3 57.42 7.306127
YER074W / 
YIL069C 
RPS24A 
/ 
RPS24B 70 11 8 0 38.24 7.175941
YBR189W / 
YPL081W ** 
RPS9B / 
RPS9A 54 16 11 0 37.24 7.17521
YDL083C / 
YMR143W 
RPS16B 
/ 
RPS16A 90 11 9 0 51.39 6.941377
YNL067W RPL9B 67 15 10 1 59.9 6.926167
YCR031C / 
YJL191W ** 
RPS14A 
/ 
RPS14B 91 10 7 0 50.72 6.878998
YGL076C / 
YPL198W ** 
RPL7A / 
RPL7B 100 19 14 0 55.92 6.874593
YOR063W RPL3 202 30 19 19 49.74 6.855889
YJL190C / 
YLR367W 
** 
RPS22A 
/ 
RPS22B 57 10 7 0 61.83 6.837139
YER056C-A 
/ YIL052C ** 
RPL34A 
/ 
RPL34B 20 9 7 0 25.41 6.598724
YMR242C / 
YOR312C 
** 
RPL20A 
/ 
RPL20B 79 14 9 0 40.78 6.592579
YGR085C / 
YPR102C ** 
RPL11B 
/ 
RPL11A 78 13 9 0 52 6.582278
YOL127W RPL25 47 10 7 7 61.54 6.345983
YMR194W  RPL36A  36 7 6 0 46.53 6.2927
YGL123W RPS2 103 17 12 12 63.14 6.193078
YGL103W RPL28 53 10 8 8 40.67 5.980146
YDR064W RPS13 106 10 7 7 43.42 5.872335
YNL209W SSB2 212 39 27 3 62.21 5.856296
YLR325C RPL38 43 5 3 3 32.91 5.664439
YLR287C-A 
/ YOR182C 
RPS30A 
/ 
RPS30B 34 4 3 0 28.13 5.619556
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Table A1 – Continued 
 
Accession 
# Gene 
tot # 
spectra 
tot non-
redun 
spectra 
tot non-
redun 
peptides
# 
unique 
% AA 
covg PAF 
YOL039W RPP2A 25 6 5 5 78.5 5.583473
YDL229W SSB1 176 37 26 2 57.82 5.555389
YAL038W CDC19 86 30 25 23 60.88 5.500046
YBR118W / 
YPR080W 
TEF2 / 
TEF1 122 27 17 0 47.06 5.396438
YMR121C RPL15B 59 13 9 2 38.54 5.323069
YGR192C TDH3 139 19 14 5 65.77 5.315131
YNL178W RPS3 73 14 12 12 55.6 5.282421
YHL001W / 
YKL006W ** 
RPL14B 
/ 
RPL14A 46 8 6 0 38.85 5.279483
YGL030W RPL30 41 6 4 4 38.68 5.256242
YJR123W RPS5 99 13 9 9 51.33 5.191901
YOR369C RPS12 20 8 6 6 46.53 5.170631
YDR471W / 
YHR010W 
** 
RPL27B 
/ 
RPL27A 47 8 6 0 43.07 5.159626
YGL031C / 
YGR148C 
** 
RPL24A 
/ 
RPL24B 42 9 6 0 22.44 5.109572
YOL040C RPS15 54 8 5 5 51.75 4.999375
YNL069C RPL16B 34 11 9 4 36.68 4.944042
YBR191W RPL21A 23 9 5 1 28.57 4.93367
YBL072C / 
YER102W 
RPS8A / 
RPS8B 46 11 7 0 34.83 4.891063
YBL087C / 
YER117W 
RPL23A 
/ 
RPL23B 108 7 5 0 44.2 4.836592
YBR181C / 
YPL090C 
RPS6B / 
RPS6A 123 13 9 0 39.24 4.815528
YBR048W / 
YDR025W 
RPS11B 
/ 
RPS11A 48 8 6 0 33.76 4.507296
YLR029C RPL15A 58 11 9 2 38.54 4.504136
YLR388W RPS29A 9 3 3 3 31.58 4.503828
YGL135W / 
YPL220W 
RPL1B / 
RPL1A 190 11 9 0 37.16 4.492363
YLR061W RPL22A 225 6 3 2 46.72 4.381801
YER165W PAB1 111 28 23 23 57.96 4.35161
YLR048W RPS0B 35 12 8 1 51.38 4.291539
YGR214W / 
YLR048W 
** 
RPS0A / 
RPS0B 42 12 8 0 25.3 4.282044
YBL027W / 
YBR084C-A 
RPL19B 
/ 
RPL19A 79 9 6 0 33.16 4.146701
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Table A1 – Continued 
 
Accession 
# Gene 
tot # 
spectra 
tot non-
redun 
spectra 
tot non-
redun 
peptides
# 
unique 
% AA 
covg PAF 
YDR418W / 
YEL054C 
RPL12B 
/ 
RPL12A 36 7 5 0 42.17 3.927509
YGR214W RPS0A 28 11 8 1 43.87 3.925207
YDL075W / 
YLR406C ** 
RPL31A 
/ 
RPL31B 60 5 4 0 35.96 3.86011
YPL131W RPL5 62 13 9 9 41.61 3.855851
YLR340W RPP0 56 13 10 10 39.94 3.855622
YGR118W / 
YPR132W 
RPS23A 
/ 
RPS23B 82 6 5 0 32.19 3.741115
YFL034C-A RPL22B 19 5 3 2 46.34 3.616113
YIL133C RPL16A 25 8 8 3 36 3.603441
YBR009C / 
YNL030W 
HHF1 / 
HHF2 11 4 3 0 28.85 3.518649
YNL301C / 
YOL120C 
RPL18B 
/ 
RPL18A 27 7 7 0 29.41 3.404173
YPL143W RPL33A 10 4 3 1 29.63 3.291098
YOR234C RPL33B 13 4 3 1 29.63 3.287311
YHR121W LSM12 27 7 5 5 35.11 3.284226
YHR141C / 
YNL162W 
RPL42B 
/ 
RPL42A 30 4 2 0 14.95 3.275467
YHR073C-B ORF 16 1 1 1 40.74 3.256268
YER131W RPS26B 12 4 4 1 32.5 2.974641
YPL271W ATP15 2 2 2 2 46.03 2.966039
YGL189C RPS26A 12 4 4 1 32.5 2.961866
YOR204W DED1 102 19 16 14 45.29 2.898418
YLL024C SSA2 69 20 16 1 40.16 2.878941
YHL015W RPS20 13 4 4 4 37.7 2.876249
YGR148C RPL24B 13 5 4 1 21.15 2.84949
YML056C IMD4 44 16 13 6 41.33 2.837181
YDL081C RPP1A 20 3 2 2 56.07 2.750275
YCL043C PDI1 92 16 13 13 36.71 2.747866
YOR332W VMA4 15 7 5 5 26.5 2.644403
YBR084W MIS1 65 28 26 25 39.86 2.636113
YNL307C MCK1 35 11 9 9 30.59 2.550074
YJR009C TDH2 25 9 9 2 41.74 2.51067
YGR215W RSM27 6 3 3 3 38.74 2.420721
YMR230W / 
YOR293W 
** 
RPS10B 
/ 
RPS10A 4 3 2 0 22.64 2.355158
YER177W BMH1 23 7 5 1 30.22 2.326277
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Accession 
# Gene 
tot # 
spectra 
tot non-
redun 
spectra 
tot non-
redun 
peptides
# 
unique 
% AA 
covg PAF 
YLR167W RPS31 14 4 3 2 22.22 2.32342
YML028W TSA1 9 5 5 5 36.04 2.315887
YLR432W IMD3 41 13 12 2 45.04 2.297429
YCL037C SRO9 43 11 9 9 40.69 2.288806
YER131W / 
YGL189C ** 
RPS26B 
/ 
RPS26A 7 3 2 0 20 2.230981
YMR188C MRPS17 14 6 6 6 29.41 2.17116
YAL005C SSA1 40 15 13 3 32.81 2.150014
YBL003C / 
YDR225W 
** 
HTA2 / 
HTA1 9 3 2 0 24.06 2.144542
YHL034C SBP1 24 7 6 6 37.29 2.121855
YLR185W RPL37A 2 2 2 2 21.35 2.030457
YDR500C RPL37B 3 2 1 1 7.87 2.026753
YKL016C ATP7 10 4 3 3 24.57 2.019182
YDR381W YRA1 14 5 4 4 15.42 2.003526
YCR009C RVS161 6 6 6 6 39.47 1.983471
YKR006C MRPL13 19 6 6 6 40 1.982095
YGL068W MNP1 23 4 3 3 20.51 1.937046
YNL071W LAT1 47 10 10 10 27.95 1.929831
YDL130W RPP1B 13 2 2 2 46.73 1.874766
YKL167C MRP49 6 3 2 2 15.94 1.872542
YGL147C / 
YNL067W 
** 
RPL9A / 
RPL9B 14 4 4 0 20.31 1.854513
YPL127C HHO1 12 5 5 5 25.87 1.798302
YJL138C / 
YKR059W 
TIF2 / 
TIF1 18 8 8 0 19.7 1.789829
YGR178C PBP1 40 14 13 13 28.22 1.777078
YNR036C ORF 4 3 3 3 40.26 1.773364
YBL030C PET9 17 6 6 5 23.82 1.742869
YOR196C LIP5 18 8 8 8 31.08 1.729842
YOL111C TMA24 7 4 4 4 31.46 1.685488
YJL052W TDH1 17 6 6 1 26.73 1.678322
YLR150W STM1 25 5 4 4 28.1 1.666944
YNL112W DBP2 16 10 10 9 27.79 1.639371
YLR029C / 
YMR121C 
** 
RPL15A 
/ 
RPL15B 27 4 4 0 23.9 1.637867
YFL016C MDJ1 27 9 8 8 25.98 1.619841
YDR385W / 
YOR133W 
EFT2 / 
EFT1 38 15 13 0 16.25 1.607907
YDR148C KGD2 25 8 7 7 25.43 1.586326
YJL205C NCE101 1 1 1 1 37.04 1.578283
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Table A1 – Continued  
 
Accession 
# Gene 
tot # 
spectra 
tot non-
redun 
spectra 
tot non-
redun 
peptides
# 
unique 
% AA 
covg PAF 
YNR051C BRE5 26 9 9 9 25.19 1.560495
YJL122W ORF 6 3 3 3 28.41 1.555452
YPL106C SSE1 42 12 11 9 22.05 1.551069
YDR432W NPL3 19 7 6 6 24.34 1.541613
 
 
 
TABLE A1- Protein abundance factors (PAF) from replicate Gis2-Tap 
purifications        
     
In 3 replicate experiments, Gis2-TAP was isolated from yeast whole cell lysate 
and coeluting proteins were analyzed by LC-MS/MS.  Proteins were identified by 
searching the acquired mass spectrometry data against a non-redundant 
database of yeast proteins using the Sequest algorithm (Eng, McCormack et al. 
1994).  The resulting output files were processed and analyzed using the 
BIGCAT software suite (McAfee, Duncan et al. 2006).  Proteins are ranked by 
their protein abundance factor (PAF), which is a non-isotopic method of 
quantifying protein abundance in mass spectrometry data.  
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TABLE A2- Proteins copurifying with ZNF9 in immunoprecipitation experiments 
 
Gene Score 
tot 
# 
spe
ctra 
tot 
non-
redun 
spectra
tot non-
redun 
peptides
# 
unique
% 
AA 
covg PAF 
ZNF9 -75.08 11 3 3 3 23.16 1.5414 
HSPB1 -69.46 11 6 5 5 30.24 2.6335 
RPL13 / 
RPL13 -60.3 8 3 3 0 13.74 1.2366 
KRT6A -59.2 10 7 7 1 14.36 1.1658 
RPS20 -57.54 9 3 3 3 22.69 2.2433 
RPS25 / 
LOC401206 -53.09 7 3 3 0 16 2.1831 
PRSS2 -49.42 7 4 3 1 15.38 1.5101 
RPSA / 
RPSA -48.88 7 3 3 0 15.25 0.9131 
RPS3A / 
RPS3A -48.46 7 3 3 0 12.88 1.0018 
HNRPA2B1 
/ 
HNRPA2B1 -44.11 7 3 3 0 12.02 0.8332 
RPS2 / 
LOC286444 -44 6 3 3 0 11.6 0.9577 
RPS19 -38.76 6 3 3 2 17.93 1.868 
RPS5 -36.84 4 1 1 1 7.35 0.4371 
HNRPC / 
HNRPC -34.25 5 2 2 0 7.59 0.6257 
RPL27A / 
LOC389435 -32.74 6 3 3 0 25.68 1.8115 
HSPA8 / 
HSPA8 -31.87 5 3 3 0 6.35 0.4231 
RPL31 / 
LOC391581 -30.4 4 1 1 0 7.2 0.6914 
HNRPA1 / 
HNRPA1 -30.38 5 3 3 0 12.81 0.8773 
KRT2A -30.03 5 4 4 3 7.2 0.6113 
RPS28 / 
LOC441618 -25.55 3 1 1 0 17.39 1.2753 
RPL18 -25.43 3 2 2 2 13.83 0.9245 
RPL8 / 
RPL8 -25.24 5 3 3 0 9.34 1.0705 
HNRPU / 
HNRPU -24.13 3 2 2 0 2.98 0.2248 
RPL12 / 
LOC344471 -23.37 4 1 1 0 5.45 0.5612 
RPS23 -22.54 3 2 2 1 16.08 1.2652 
RPL29 / 
LOC283412 -22.34 4 2 2 0 14.47 1.1266 
TUBB2 -19.91 4 3 3 1 8.09 0.602 
LOC389127 -19.51 3 1 1 1 10.77 0.6686 
HIST1H4I / 
HIST1H4A  -19.34 3 2 2 0 21.36 1.7595 
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TABLE A2 – Continued 
 
Gene Score 
tot # 
spect
ra 
tot 
non-
redun 
spectra
tot non-
redun 
peptides
# 
unique
% 
AA 
covg PAF 
THOC4 -19.07 3 2 2 2 10.51 0.7438 
ALDOA / 
ALDOA / 
ALDOA -18.42 2 1 1 0 3.85 0.2537 
RPL21 / 
LOC387753 -18.42 2 1 1 0 9.38 0.5386 
CCT2 -18.42 2 1 1 1 2.99 0.1739 
RPS11 -18.02 3 2 2 2 11.39 1.0851 
HNRPH1 -17.89 3 2 2 1 5.12 0.4063 
RPS8 -16.22 2 1 1 1 6.25 0.4131 
NSEP1 -16.22 2 1 1 1 5.86 0.2784 
FLJ33718 -15.78 3 1 1 1 4.92 0.2691 
FAU -15.46 3 2 2 2 8.27 1.3899 
RUVBL1 -15.13 3 2 2 2 4.82 0.3982 
ILF3 / ILF3 -14.84 2 1 1 0 1.42 0.1315 
SFRS2 / 
SRP46 -14.53 2 1 1 0 3.62 0.3925 
RPLP2 -14.41 3 2 2 2 26.96 1.7145 
RPS21 -14.27 3 2 2 2 18.07 2.1951 
RPL24 -12.88 2 1 1 1 5.1 0.5625 
PRSS3 -12.55 2 2 2 1 11.34 0.7491 
LOC388255 
/ 
LOC390714 -11.9 2 1 1 0 0.37 0.048 
RPL14 -11.44 2 2 2 1 13.89 0.851 
RPS4X -11.02 2 2 2 1 8.37 0.6757 
HSPD1 / 
HSPD1 -10.19 2 2 2 0 3.49 0.3276 
GLDC -9.13 2 1 1 1 1.47 0.0886 
RPS27 / 
LOC389112 -9.11 2 1 1 0 13.1 1.057 
RPLP1 / 
LOC440927 -8.36 2 1 1 0 14.04 0.8685 
 
  
TABLE A2- Proteins copurifying with ZNF9 in immunoprecipitation experiments 
ZNF9 was immunoprecipitated from HeLa cell lysates and the coeluting proteins 
were analyzed by LC-MS/MS.  Proteins were identified by searching the acquired 
mass spectrometry data against a non-redundant database of human proteins 
using the Sequest algorithm (Eng, McCormack et al. 1994).  The resulting output 
files were processed and analyzed using the BIGCAT software suite (McAfee, 
Duncan et al. 2006).  Proteins were considered significant if over 2 spectra were 
acquired and confidently matched.  
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